WO2001038304A1 - Heterocyclic ketone and thioester compounds and uses - Google Patents

Heterocyclic ketone and thioester compounds and uses Download PDF

Info

Publication number
WO2001038304A1
WO2001038304A1 PCT/US2000/023742 US0023742W WO0138304A1 WO 2001038304 A1 WO2001038304 A1 WO 2001038304A1 US 0023742 W US0023742 W US 0023742W WO 0138304 A1 WO0138304 A1 WO 0138304A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
dimethyl
phenyl
oxo
pharmaceutical composition
Prior art date
Application number
PCT/US2000/023742
Other languages
French (fr)
Inventor
Gregory S. Hamilton
Jia-He Li
Original Assignee
Gpi Nil Holdings, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gpi Nil Holdings, Inc. filed Critical Gpi Nil Holdings, Inc.
Priority to CA002391575A priority Critical patent/CA2391575A1/en
Priority to MXPA02005206A priority patent/MXPA02005206A/en
Priority to EP00959575A priority patent/EP1233945A1/en
Priority to AU70869/00A priority patent/AU784388B2/en
Priority to JP2001539860A priority patent/JP2003514893A/en
Publication of WO2001038304A1 publication Critical patent/WO2001038304A1/en
Priority to HK02108037.6A priority patent/HK1046530A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates to neurotrophic, low molecular weight, small molecule heterocyclic ketone and thioester compounds, and their use for effecting neuronal activities in animals, including treating neurological disorders.
  • neurodegenerative disorders such as senile dementia of the Alzheimer's type (SDAT or Alzheimer's disease), Parkinson's disease and amyotrophic lateral sclerosis (ALS) , may occur due to the loss, or decreased availability, of a neurotrophic substance specific for a particular population of neurons affected in the disorder.
  • SDAT Alzheimer's type
  • ALS amyotrophic lateral sclerosis
  • Alzheimer's disease results from a decrease or loss of nerve growth factor (NGF) . It has thus been proposed to treat SDAT patients with exogenous nerve growth factor or other neurotrophic proteins, such as brain derived growth factor, glial derived growth factor, ciliary neurotrophic factor and neur ⁇ tropin-3, to increase the survival of degenerating neuronal populations.
  • NGF nerve growth factor
  • immunosuppressant drugs with neurotrophic activity are relatively small and display excellent bioavailability and specificity.
  • immunosuppressants exhibit a number of potentially serious side effects, including nephrotoxicity, such as impairment of glomerular filtration and irreversible interstitial fibrosis (Kopp et al., J. Am . Soc . Nephrol . , 1991, 1:162); neurological deficits, such as involuntary tremors, or non-specific cerebral angina, such as non-localized headaches (De Groen et al., N. Engl . J. Med. , 1987, 317:861); and vascular hypertension, with complications resulting therefrom (Kahan et al., N. Engl . J. Med. , 1989, 321:1725).
  • the present invention provides small molecule compounds for enhancing neurite outgrowth, and promoting neuronal growth and regeneration in various neuropathological situations where neuronal repair can be facilitated, including: peripheral nerve damage caused by physical injury or disease state such as diabetes; physical damage to the central nervous system (spinal cord and brain) ; brain damage associated with stroke; and neurological disorders relating to neurodegeneration, such as Parkinson's disease, HuntingtonY Disease, SDAT (Alzheimer's disease) and amyotrophic lateral sclerosis (ALS) .
  • the present invention relates to neurotrophic, low molecular weight, small molecule heterocyclic ketone or thioester compounds.
  • the compounds are non-immunosuppressive .
  • the compounds of the present invention have an affinity for FKBP-type immunophilins, such as FKBP12; and affinity binding or interaction may inhibit the prolyl-peptidyl cis-trans isomerase, or rotamase, activity of the binding protein.
  • the present invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising:
  • the present invention further relates to a method of effecting a neuronal activity in an animal, comprising administering to said animal an effective amount of a neurotrophic, low molecular weight, small molecule heterocyclic ketone or thioester compound.
  • the present invention relates to a compound of formula II:
  • n 1 or 2;
  • X is 0 or S;
  • Z is selected from the group consisting of S, CH 2 , CHRi, CR X R 2 , and a bond;
  • R x , R 2 , and R 3 are independently selected from the group consisting of CYCs straight or branched chain alkyl, C 2 -C 5 straight or branched chain alkenyl, and Ar, wherein said R l r R 2 , or R 3 is unsubstituted or substituted with one or more halo, trifluoromethyl, nitro, C ⁇ _-C 6 straight or branched chain alkyl, C 2 -C 6 straight or branched chain alkenyl, hydroxy, CYC,, alkoxy, C 2 -C 4 alkenyloxy, phenoxy, benzyloxy, amino, or Ar;
  • R 4 is selected from the group consisting of Ci-Cg straight or branched chain alkyl, C 2 -C 9 straight or branched chain alkenyl, C 3 -C 8 cycloalkyl, C 5 -C 7 cycloalkenyl, and Ar; and
  • Ar is aryl
  • the present invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising:
  • the present invention further relates to a method of effecting a neuronal activity in an animal, comprising administering to said animal an effective amount of a compound of formula II.
  • FIG. 1(A) is a representative photomicrograph of untreated sensory neurons.
  • FIG. 1(B) is a representative photomicrograph of compound 1 (10 pM) promoting neurite outgrowth in sensory neurons.
  • FIG. 1(C) is a representative photomicrograph of compound 1 (1 nM) promoting neurite outgrowth in sensory neurons.
  • FIG. 1(D) is a representative photomicrograph of compound 1 (1 ⁇ M) promoting neurite outgrowth in sensory neurons .
  • FIG. 2(A) is a representative photomicrograph of untreated sensory neurons.
  • FIG. 2(B) is a representative photomicrograph of a related compound, 2-Phenyl-l-ethyl (25) -1- (3, 3-dimethyl- 1, 2-dioxopentyl) -2-pyrrolidinecarbothioate, (10 pM) promoting neurite outgrowth in sensory neurons.
  • FIG. 2(C) is a representative photomicrograph of a related compound, 2-Phenyl-l-ethyl (2S) -1- (3, 3-dimethyl- 1, 2-dioxopentyl) -2-pyrrolidinecarbothioate, (1 nM) promoting neurite outgrowth in sensory neurons.
  • FIG. 2(D) is a representative photomicrograph of a related compound, 2-Phenyl-l-ethyl (25) -1- ( 3, 3-dimethyl- 1, 2-dioxopentyl) -2-pyrrolidinecarbothioate, (100 nM) promoting neurite outgrowth in sensory neurons.
  • FIG. 3(A) is a representative photomicrograph of untreated sensory neurons.
  • FIG. 3(B) is a representative photomicrograph of a related compound, 2-Phenyl-l-ethyl 1- (3, 3-dimethyl-l , 2- dioxopentyl) -2-piperidinecarbothioate, (10 pM) promoting neurite outgrowth in sensory neurons .
  • FIG. 3(C) is a representative photomicrograph of a related compound, 2-Phenyl-l-ethyl 1- (3, 3-dimethyl-l, 2- dioxopentyl) -2-piperidinecarbothioate, (1 nM) promoting neurite outgrowth in sensory neurons.
  • FIG. 3(D) is a representative photomicrograph of a related compound, 2-Phenyl-l-ethyl 1- (3, 3-dimethyl-l, 2- dioxopentyl) -2-piperidinecarbothioate, (100 nM) promoting neurite outgrowth in sensory neurons.
  • FIG. 4 presents quantitation for the recovery of TH-positive dopaminergic neurons in the striatum of animals receiving compound 1 and related compounds.
  • Alkenyl means a branched or unbranched unsaturated hydrocarbon chain comprising a designated number of carbon atoms.
  • C 2 -C 6 straight or branched alkenyl hydrocarbon chain contains 2 to 6 carbon atoms having at least one double bond, and includes but is not limited to substituents such as ethenyl, propenyl, iso-propenyl, butenyl, iso-butenyl, tert-butenyl, n-pentenyl, n-hexenyl, and the like.
  • alkenyl may also refer to an unsaturated hydrocarbon chain wherein any of the carbon atoms of said alkenyl are optionally replaced with 0, NH, S, or S0 2 .
  • carbon 2 of 4-pentene can be replaced with 0 to form (2-propene) oxymethyl .
  • Alkoxy refers to the group -OR wherein R is alkyl as herein defined.
  • R is a branched or unbranched saturated hydrocarbon chain containing 1 to 6 carbon atoms.
  • Alkyl means a branched or unbranched saturated hydrocarbon chain comprising a designated number of carbon atoms.
  • Ci-Cg straight or branched alkyl hydrocarbon chain contains 1 to 6 carbon atoms, and includes but is not limited to substituents such as methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, n-pentyl, n-hexyl, and the like.
  • alkyl may also refer to a hydrocarbon chain wherein any of the carbon atoms of said alkyl are optionally replaced with 0, NH, S, or S0 2 .
  • carbon 2 of n-pentyl can be replaced with 0 to form propyloxymethyl .
  • R or “R n”, where n is a number, is used to designate various substituents. These R groups are independently selected. Thus, for example, the fact that R, may be a branched alkyl in one context does not require that R x be the same branched alkyl, and does not prohibit that R x be, for example, a straight chain alkenyl in another context in the same molecule. It is intended that all “R n " are selected independently of all other “R n ", whether or not the term “independently selected” is used.
  • Aryl or “aromatic” refers to an aromatic carbocyclic or heterocyclic group having a single ring, for example a phenyl ring; multiple rings, for example biphenyl; or multiple condensed rings in which at least one ring is aromatic, for example naphthyl, 1,2,3,4- tetrahydronaphthyl, anthryl, or phenanthryl .
  • the ring(s) of an aryl moiety can be unsubstituted or substituted with one or more substituents including, but not limited to, halo, hydroxyl, nitro, trifluoromethyl, straight or branched chain alkyl or alkenyl, C 1 -C 4 alkoxy, C x -C 4 alkenyloxy, phenoxy, benzyloxy, or amino; a heterocyclic ring may contain 1-6 heteroatom (s) selected from the group consisting of 0, N, and S.
  • the substituents attached to a phenyl ring portion of an aryl moiety in the compounds of the invention may be configured in the ortho-, meta-, or para- orientation (s) , with the para- orientation being preferred.
  • Ar or “Ar n ", where n is a number, is used to designate various substituents. As indicated throughout, these Ar groups are independently selected. Thus, for example, the fact that Ar may be phenyl in one context does not require that Ar be phenyl, nor prohibit that Ar be, for example, pyridyl in another context in the same molecule. It is intended that all “Ar” are selected independently of all other "Ar”, whether or not the term “independently selected” is used.
  • Carbocycle or “carbocyclic” refers to an organic cyclic moiety in which the cyclic skeleton is comprised of only carbon atoms
  • heterocycle or “heterocyclic” refers to an organic cyclic moiety in which the cyclic skeleton contains one or more heteroatoms selected from nitrogen, oxygen, or sulfur, and which may or may not include carbon atoms
  • the term “carbocycle” refers to a carbocyclic moiety containing the indicated number of carbon atoms.
  • C 3 -C 8 cycloalkyl refers to an organic cyclic substituent in which three to eight carbon atoms form a three, four, five, six, seven, or eight-membered ring, including, for example, a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl ring .
  • Carbocyclic each includes within its scope a single ring system, multiple fused rings (for example, bicyclic, tricyclic, or other similar bridged ring systems or substituents, e.g. adamantyl) or multiple condensed ring systems.
  • a cyclic structure may comprise bi-, or tri-, or multiple condensed rings, bridged ring systems, or combinations thereof.
  • Halo refers to fluoro, chloro, bromo or iodo, unless otherwise indicated.
  • Heterocycle refers to a saturated, unsaturated, or aromatic carbocyclic group having a single ring, multiple fused rings (for example, bicyclic, tricyclic, or other similar bridged ring systems or substituents), or multiple condensed rings, and having at least one heteroatom such as nitrogen, oxygen, or sulfur within at least one of the rings.
  • This term also includes "Heteroaryl,” which refers to a heterocycle in which at least one ring is aromatic. Any heterocyclic or heteroaryl group can be unsubstituted or optionally substituted with one or more groups, as defined above. Further, bi- or tricyclic heteroaryl moieties may comprise at least one ring which is either completely • or partially saturated.
  • heterocyclic moieties may exist in several isomeric forms, all of which are encompassed by the present invention.
  • a 1, 3, 5-triazine moiety is isomeric to a 1, 2, -triazine group.
  • Such positional isomers are to be considered within the scope of the present invention.
  • the heterocyclic or heteroaryl groups can be bonded to other moieties in the compounds of the present invention. The point (s) of attachment to these other moieties is not to be construed as limiting on the scope of the invention.
  • a pyridyl moiety may be bound to other groups through the 2-, 3-, or 4-position of the pyridyl group. All such configurations are to be construed as within the scope of the present invention.
  • Examples of heterocyclic or heteroaryl moieties included in the scope of the present invention may include, but are not limited to, the following:
  • “Isomers” are different compounds that have the same molecular formula. “Stereoisomers” are isomers that differ only in the way the atoms are arranged in space. "Enantiomers” are a pair of stereoisomers that are non-superimposable mirror images of each other. “Diastereoisomers” are stereoisomers which are not mirror images of each other. “Racemic mixture” means a mixture containing equal parts of individual enantiomers. “Non-racemic mixture” is a mixture containing unequal parts of individual enantiomers or stereoisomers .
  • Low molecular weight, small molecule compounds include, without limitation, molecules which are smaller in size, molecular weight, or both in relation to the compounds Rapamycin, Cyclosporin, and FK506.
  • Neurotrophic includes without limitation the ability to stimulate neuronal regeneration or growth, the ability to prevent or treat neurodegeneration, or both.
  • Non-immunosuppressive refers to the inability of the compounds of the present invention to suppress an immune response when compared to a control such as FK506 or cyclosporin A.
  • Assays for determining immunosuppression are well known to those of ordinary skill in the art. Specific, non-limiting examples of well known assays include PMA and OKT3, wherein mitogens are used to stimulate proliferation of human peripheral blood lymphocytes (PBC) and the tested compounds are evaluated on their ability to inhibit such proliferation.
  • PBC peripheral blood lymphocytes
  • “Pharmaceutically acceptable carrier” refers to any carrier, diluent, excipient, suspending agent, lubricating agent, adjuvant, vehicle, delivery system, emulsifier, disintegrant , absorbant, preservative, surfactant, colorant, flavorant, or sweetener.
  • the compounds of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir in dosage formulations containing conventional non-toxic pharmaceutically- acceptable carriers, adjuvants and vehicles.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, intraperitoneally, intrathecally, intraventricularly, intrasternal, and intracranial injection or infusion techniques.
  • “Pharmaceutically acceptable salt” refers to an organic or inorganic salt which is useful in the treatment of a warm-blooded animal in need thereof. Such salts can be acid or basic addition salts, depending on the nature of the inventive compound to be used.
  • a salt may be formed by treatment of the inventive compound with a basic compound, particularly an inorganic base.
  • Preferred inorganic salts are those formed with alkali and alkaline earth metals such as lithium, sodium, potassium, barium, and calcium.
  • Preferred organic base salts include, for example, ammonium, dibenzylammonium, benzylammonium, 2- hydroxyethylammonium, bis (2-hydroxyethyl ) ammonium, phenylethylbenzylamine, dibenzyl-ethylenediamine, and like salts.
  • salts of acidic moieties may include, for example, those salts formed with procaine, quinine and N-methylglucosamine, plus salts formed with basic amino acids such as glycine, ornithine, histidine, phenylglycine, lysine and arginine.
  • suitable base salts, esters, or solvates include magnesium salts; salts with organic bases, such as dicyclohexylamine salts; and N-methyl-D-glucamine .
  • An especially preferred salt is a sodium or potassium salt of an inventive compound.
  • a salt is formed by the treatment of the desired inventive compound with an acidic compound, particularly an inorganic acid.
  • Preferred inorganic salts of this type may include, for example, hydrochloric, hydrobromic, hydroiodic, sulfuric, phosphoric, or like salts.
  • Preferred organic salts of this type may include, for example, salts formed with formic, acetic, succinic, citric, lactic, maleic, fumaric, palmitic, cholic, pamoic, mucic, d- glutamic, d-camphoric, glutaric, glycolic, phthalic, tartaric, lauric, stearic, salicyclic, methanesulfonic, benzenesulfonic, para-toluenesulfonic, sorbic, puric, benzoic, cinnamic, and like organic acids.
  • Suitable acids are adipate, alginate, aspartate, benzenesulfonate, bisulfate, butyrate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, 2-hydroxyethanes- ulfonate, methanesulfonate, naphthylate, 2- naphthalenesulfonate, nicotinate, oxalate, thiocyanate, tosylate, and undecanoate.
  • An especially preferred salt of this type is a hydrochloride or sulfate salt of the desired inventive compound.
  • the basic nitrogen- containing groups can be quarternized with such agents as: 1) lower alkyl halides, such as methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; 2) dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates; 3) long chain alkyls such as decyl, lauryl, myristyl, and stearyl substituted with one or more halide such as chloride, bromide, and iodide; and 4) aralkyl halides like benzyl and phenethyl bromide and others .
  • esters of a carboxylic acid or hydroxyl containing group including a metabolically labile ester or a prodrug form of an inventive compound.
  • a metabolically labile ester is one which may produce, for example, an increase in blood levels and prolong the efficacy of the corresponding non-esterified form of the compound.
  • a prodrug form is one which is not in an active form of the molecule as administered but which becomes therapeutically active after some in vivo activity or biotransformation, such as, for example, metabolism by enzymatic or hydrolytic cleavage.
  • Esters of an inventive compound may include, for example, methyl, ethyl, propyl, and butyl esters, as well as other suitable esters formed between an acidic moiety and a hydroxyl containing moiety.
  • Metabolically labile esters may include, for example, methoxymethyl, ethoxymethyl, iso-propoxymethyl, ⁇ -methoxyethyl, and groups such as - ( (C- L -C alkyloxy) ethyl; methoxyethyl, ethoxyethyl, propoxyethyl, and iso-propoxyethyl; 2-oxo- 1, 3-dioxolen-4-ylmethyl groups, such as 5-methyl-2-oxo- 1, 3, dioxolen-4-ylmethyl; C ⁇ alkylthiomethyl groups, for example, methylthiomethyl, ethylthiomethyl, isopropylthiomethyl; acyloxymethyl groups, for example,
  • the compounds of the invention may exist as crystalline solids which can be crystallized from common solvents such as ethanol, N, N-dimethyl-formamide, water, or the like.
  • crystalline forms of the compounds of the invention may exist as solvates and/or hydrates of the parent compounds or their pharmaceutically acceptable salts, esters, or solvates. All of such forms likewise are to be construed as falling within the scope of the invention.
  • Phenyl refers to any possible isomeric phenyl radical, optionally monosubstituted or multisubstituted with substituents selected from the group consisting of alkyl, alkoxy, hydroxy, halo, and haloalkyl.
  • Preventing neurodegeneration includes (1) the ability to inhibit or prevent neurodegeneration in patients newly diagnosed as having a neurodegenerative disease or at risk of developing a new neurodegenerative disease and (2) the ability to inhibit or prevent further neurodegeneration in patients who are already suffering from, or have symptoms of, a neurodegenerative disease .
  • Treating covers any treatment of a disease, a condition, or both in an animal, particularly a human, and includes: (i) preventing a disease or condition from occurring in a subject which may be predisposed to the disease or condition but has not yet been diagnosed as having it;
  • Warm-blooded animal or “animal” includes a mammal, including a member of the human, equine, porcine, bovine, murine, canine, or feline species.
  • the term “warm-blooded animal” or “animal” may also be referred to as a "patient”.
  • a warm blooded animal in need thereof refers to a warm-blooded animal which is susceptible to a disorder due to genetic or environmental conditions or predispositions. This term also refers to a warm blooded animal which has already suffered some degree of injury or damage because of genetic or environmental conditions to which the animal has been exposed or to which it is or was predisposed. Environmental conditions can include treatment with a therapeutic compound, as well as other types of injury or insult.
  • the present invention relates to low molecular weight, small molecule neurotrophic compounds.
  • the compounds of the present invention do not exert any significant immunosuppressive activity.
  • the compounds of the present invention may bind to, or otherwise interact with, FKBP-type immunophilins, such as FKBP12; such binding or interaction may inhibit the prolyl-peptidyl cis-trans isomerase, or rotamase, activity of the binding protein.
  • the compound of the present invention has a molecular weight no more than about 800 daltons. In a more preferred embodiment, the compound of the present invention has a molecular weight no more than about 500 daltons. In a particularly preferred embodiment, the compound of the present invention has a molecular weight no more than about 330 daltons.
  • the compound of the present invention exhibits a Chick Dorsal Root Ganglion Neurite Outgrowth Assay ("DRG") ED 50 value which is less than about 10 nM. In a more preferred embodiment, the compound of the present invention exhibits a DRG ED 50 value which is less than about 1.0 nM. In a particularly preferred embodiment, the compound of the present invention exhibits a DRG ED 50 value which is less than about 0.1 nM.
  • DRG Chick Dorsal Root Ganglion Neurite Outgrowth Assay
  • the compound of the present invention exhibits an MPTP Assay value which is greater than about 20% recovery of TH-stained dopaminergic neurons. In a more preferred embodiment, the compound of the present invention exhibits an MPTP Assay value which is greater than about 35% recovery of TH-stained dopaminergic neurons. In a particularly preferred embodiment, the compound of the present invention exhibits an MPTP Assay value which is greater than about 50% recovery of TH-stained dopaminergic neurons .
  • a and B together with the nitrogen and carbon atoms to which they are respectively attached, form a 5- 7 membered saturated or unsaturated heterocyclic ring containing any combination of CH 2 , 0, S, SO, S0 2 , NH, or NR 4 in any chemically stable oxidation state;
  • X is either 0 or S
  • Z is either S, CH 2 , CHR,_, CR X R 2 , or a bond;
  • W and Y are independently 0, S, CH 2 , or H 2 ;
  • R x , R 2 , and R 3 are independently Ci-Cg straight or branched chain alkyl or alkenyl, which is substituted in one or more position (s) with (ArY, (Ar-Y connected by a Ci-Cg straight or branched chain alkyl or alkenyl, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkyl connected by a Ci-Cg straight or branched chain alkyl or alkenyl, or Ar 2 ; n is 1 or 2;
  • R 4 is either Cj-Cg straight or branched chain alkyl, C 2 -C 9 straight or branched chain alkenyl, C 3 -C 8 cycloalkyl, C 5 -C 7 cycloalkenyl or Rr l r wherein said alkyl, alkenyl, cycloalkyl or cycloalkenyl is either unsubstituted or substituted in one or more position (s) with C ⁇ ⁇ C 4 straight or branched chain alkyl or alkenyl, or hydroxyl; and Ar x and Ar 2 are each, independently, an aryl group.
  • a preferred embodiment of an aryl group is a mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein the ring is either unsubstituted or substituted in one or more position (s) with halo, hydroxyl, nitro, trifluoromethyl, C ⁇ Cg straight or branched chain alkyl or alkenyl, C ⁇ C,, alkoxy, C x -C 4 alkenyloxy, phenoxy, benzyloxy, or amino; wherein the individual ring sizes are 5-6 members; and wherein the heterocyclic ring contains 1-6 heteroatom (s) selected from the group consisting of 0, N, and S.
  • Suitable mono- and bicyclic, carbo- and heterocyclic rings include, without limitation, naphthyl, indolyl, thioindolyl, furyl, thiazolyl, thienyl, pyridyl, quinolinyl, isoquinolinyl, fluorenyl, phenyl, and benzyl.
  • R l r R 2 , and R 3 are independently selected from the group consisting of Ci-Cj straight or branched chain alkyl, C 2 -C 5 straight or branched chain alkenyl, and Ar, wherein said R l f R 2 , or R 3 is unsubstituted or substituted with one or more halo, trifluorormethyl, nitro, Ci-Cg straight or branched chain alkyl, C 2 -C 5 straight or branched chain alkenyl, hydroxy, C x -C 4 alkoxy, C 2 -C 4 alkenyloxy, phenoxy, benzyloxy, amino, or Ar; R 4 is selected from the group consisting of Ci-Cg straight or branched chain alkyl, C 2 -C 9 straight or branched chain alkenyl, C 3 -C 8 cycloalkyl, C 5 -C 7 cycloalkenyl, and Ar; and
  • Ar is aryl.
  • a preferred embodiment for Ar is phenyl, benzyl, pyridyl, fluorenyl, thioindolyl, or naphthyl, wherein said Ar is unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, trifluoromethyl, hydroxy, nitro, C ⁇ Cg straight or branched chain alkyl, C 2 -C 6 straight or branched chain alkenyl, Ci-C,, alkoxy, C 2 -C 4 alkenyloxy, phenoxy, benzyloxy, and amino.
  • a particularly preferred embodiment of Formula II is a compound wherein n is 1, X is 0, Z is CH 2 , R 3 is 3- pyridylpropyl, and R 4 is 1, 1-dimethylpropyl .
  • Another particularly preferred embodiment of Formula II is a compound wherein n is 2 , X is 0, Z is CH 2j R 3 is 4-phenylbutyl, and R 4 is 1, 1-dimethylpropyl .
  • Another particularly preferred embodiment of Formula II is a compound wherein n is 1, X is 0, Z is CH 2 ⁇ R 3 is 2-phenylethyl, and R 4 is tert-butyl.
  • Another particularly preferred embodiment of Formula II is a compound wherein n is 1, X is 0, Z is CH 2/ R 3 is 3- ( -hydroxyphenyl) propyl, and R 4 is 1,1- dimethylpropyl .
  • the most preferred embodiments of Formula II are ( 2 S ) -3, 3-dimethyl-l- [2- ( 5- ( 3-pyridyl) pyrrolidinyl] pentane-1, 2-dione; 2- ( ⁇ l-oxo-6-phenyl ⁇ - hexyl) (2S) -1- (3, 3-dimethyl-l, 2-dioxopentyl) piperidine; 2- (l-Oxo-4-phenyl) -butyl-1- (3, 3-dimethyl-l, 2- dioxobutyl) pyrrolidine; and (2S) -3, 3-dimethyl-l- [2- (5- ( 4-hydroxyphenyl) pentanoyl) pyyrolidinyl ] pentane-1, 2- dione .
  • A, B, and C are independently CH 2 , 0, S, SO, S0 2 , NH, or NR 4 ;
  • X is 0 or S
  • Z is S, CH 2 , CHR X , or CR ⁇ ;
  • R l f R 2 , and R 3 are independently C ⁇ Cg straight or branched chain alkyl or alkenyl, which is substituted in one or more position (s) with (ArY, (Ar n connected by a Ci-Cg straight or branched chain alkyl or alkenyl, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkyl connected by a C ⁇ Cg straight or branched chain alkyl or alkenyl, Ar 2 , or a combination thereof; n is 1 or 2;
  • R 4 is either straight or branched chain alkyl or alkenyl, C 3 -C 8 cycloalkyl, C 5 -C 7 cycloalkenyl or Ar : , wherein said alkyl, alkenyl, cycloalkyl or cycloalkenyl is either unsubstituted or substituted in one or more position (s) with C ⁇ C,, straight or branched chain alkyl or alkenyl, hydroxyl, or a combination thereof; and r !
  • Ar 2 are independently a mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein the ring is either unsubstituted or substituted in one to three position (s) with halo, hydroxyl, nitro, trifluoromethyl, Ci-Cg straight or branched chain alkyl or alkenyl, C ⁇ -C,, alkoxy, C ⁇ C, alkenyloxy, phenoxy, benzyloxy, amino or a combination thereof; wherein the individual ring sizes are 5-6 members; and wherein the heterocyclic ring contains 1-6 heteroatom ( s) selected from the group consisting of 0, N, S, and a combination thereof.
  • a further preferred embodiment of this invention is a compound of formula IV: or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein: A, B, C, and D are independently CH 2 , 0, S, SO, S0 2 , NH, or NR 4 ;
  • X is 0 or S
  • R ⁇ _, R 2 , and R 3 are independently C ⁇ Cg straight or branched chain alkyl or alkenyl, which is substituted in one or more position (s) with (ArY, (ArY connected by a Ci-Cg straight or branched chain alkyl or alkenyl, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkyl connected by a C ⁇ Cg straight or branched chain alkyl or alkenyl, Ar 2 , or a combination thereof; n is 1 or 2;
  • R 4 is either C ⁇ _-C 9 straight or branched chain alkyl or alkenyl, C 3 -C 8 cycloalkyl, C 5 -C 7 cycloalkenyl or Ar x , wherein said alkyl, alkenyl, cycloalkyl or cycloalkenyl is either unsubstituted or substituted in one or more position (s) with Ci-C,) straight or branched chain alkyl or alkenyl, hydroxyl, or a combination thereof; and
  • Ar ! and Ar 2 are independently a mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein the ring is either unsubstituted or substituted in one to three position (s) with halo, hydroxyl, nitro, trifluoromethyl, Ci-Cg straight or branched chain alkyl or alkenyl, C 1 -C 4 alkoxy, C ⁇ C,, alkenyloxy, phenoxy, benzyloxy, amino, or a combination thereof; wherein the individual ring sizes are 5-6 members; and wherein the heterocyclic ring contains 1-6 heteroatom (s) selected from the group consisting of 0, N, S, and a combination thereof.
  • the compounds of this invention possess at least one asymmetric center and thus can be produced as mixtures of stereoisomers or as individual R- and S- stereoisomers .
  • the individual enantiomers may be obtained by using an optically active starting material, by resolving a racemic or non-racemic mixture of an intermediate at some appropriate stage of the synthesis, or by resolving a compound of the present invention. It is understood that the individual R- and S- stereoisomers as well as mixtures (racemic and non- racemic) of stereoisomers are encompassed by this invention.
  • the S-stereoisomer is most preferred.
  • the compounds of formulas I to IV may be prepared by a variety of synthetic sequences that utilize established chemical transformations.
  • the general pathway to the present compounds is described in Scheme I.
  • Starting compounds may be reacted with a variety of alkenyl magnesium halides to form olefin intermediates (1) , which are in turn reacted sequentially with trifluroacetic acid, then methyl oxalyl chloride and triethylamine.
  • the resulting oxamates (2) may be reacted with a variety of carbon nucleophiles, such as Rj-MgCl, to obtain further olefin intermediates (3) .
  • These intermediates are then reacted with a variety of organohalogen compounds, such as R 2 -Br, to produce product (4) , which is hydrogenated to produce compounds of the present invention (5) .
  • the present invention further relates to the use of a compound of the present invention in the preparation of a medicament for effecting a neuronal activity in an animal .
  • the present invention relates to a method of effecting a neuronal activity in an animal, comprising administering to said animal a neurotrophically effective amount of a compound of the present invention.
  • the compounds of this invention can be periodically administered to a patient undergoing treatment for neurological disorders or for other reasons in which it is desirable to stimulate neuronal regeneration and growth, such as in various peripheral neuropathic and neurological disorders relating to neurodegeneration.
  • the compounds of this invention can also be administered to mammals other than humans for treatment of various mammalian neurological disorders.
  • novel compounds of the present invention possess an excellent degree of neurotrophic activity. This activity is useful in the stimulation of damaged neurons, the promotion of neuronal regeneration, the prevention of neurodegeneration, and in the treatment of several neurological disorders known to be associated with neuronal degeneration and peripheral neuropathies.
  • the neurological disorders include but are not limited to: trigeminal neuralgia, glossopharyngeal neuralgia, Bell's Palsy, myasthenia gravis, muscular dystrophy, amyotrophic lateral sclerosis, progressive muscular atrophy, progressive bulbar inherited muscular atrophy, herniated, ruptured or prolapsed invertebrate disk syndromes, cervical spondylosis, plexus disorders, thoracic outlet destruction syndromes, peripheral neuropathies such as those caused by lead, dapsone, ticks, prophyria, Gullain-Barre syndrome, Alzheimer's disease, Huntington' s Disease, or Parkinson's disease.
  • the compounds may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally, or via an implanted reservoir in dosage formulations containing conventional non-toxic pharmaceutically- acceptable carriers, adjuvants, and vehicles.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, intraperitoneally, intrathecally, intraventricularly, intrasternal, and intracranial injection or infusion techniques.
  • the compounds should readily penetrate the blood-brain barrier when peripherally administered. Compounds which cannot penetrate the blood-brain barrier can be effectively administered by an intraventricular route.
  • the compounds may be administered in the form of sterile injectable preparations, for example, as sterile injectable aqueous or oleaginous suspensions. These suspensions, may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparations may also be sterile injectable solutions or suspensions in non-toxic parenterally-acceptable diluents or solvents, for example, as solutions in 1,3- butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as solvents or suspending mediums.
  • any bland fixed oil such as a synthetic mono- or di- glyceride may be employed.
  • Fatty acids such as oleic acid and its glyceride rierivatives, including olive oil and castor oil, especially in their polyoxyethylated versions, are useful in the preparation of injectables.
  • These oil solutions or suspensions may also contain long-chain alcohol diluents or dispersants.
  • the compounds may be administered orally in the form of capsules, tablets, aqueous suspensions, or solutions.
  • Tablets may contain carriers such as lactose and corn starch, and/or lubricating agents such as magnesium stearate.
  • Capsules may contain diluents including lactose and dried corn starch.
  • Aqueous suspensions may contain emulsifying and suspending agents combined with the active ingredient.
  • the oral dosage forms may further contain sweetening, flavoring, coloring agents, or combinations thereof.
  • the compounds may also be administered rectally in the form of suppositories.
  • These compositions can be prepared by mixing the drug with a suitable non- irritating excipient which is solid at room temperature, but liquid at rectal temperature and, therefore, will melt in the rectum to release the drug.
  • suitable non- irritating excipient include cocoa butter, beeswax, and polyethylene glycols.
  • the compounds may be administered topically, especially when the conditions addressed for treatment involve areas or organs readily accessible by topical application, including neurological disorders of the eye, the skin, or the lower intestinal tract. Suitable topical formulations can be readily prepared for each of these areas.
  • the compounds can be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as a solution in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride.
  • the compounds may be formulated into ointments, such as petrolatum, for ophthalmic use.
  • the compounds can be formulated into suitable ointments containing the compounds suspended or dissolved in, for example, mixtures with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax, and water.
  • the compounds can be formulated into suitable lotions or creams containing the active compound suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, 2- octyldodecanol, benzyl alcohol, and water.
  • Topical application to the lower intestinal tract can be effected in a rectal suppository formulations (see above) or in suitable enema formulations.
  • Dosage levels on the order of about 0.1 mg to about 10,000 mg of the active ingredient compound are useful in the treatment of the above conditions, with preferred levels of about 0.1 mg to about 1,000 mg.
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
  • a specific dose level for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the rate of excretion; drug combination; the severity of the particular disease being treated; and the form of administration.
  • the compounds can be administered with other neurotrophic agents such as neurotrophic growth factor, brain derived growth factor, glial derived growth factor, cilial neurotrophic factor, insulin growth factor and active truncated derivatives thereof, acidic fibroblast growth factor, basic fibroblast growth factor, platelet-derived growth factors, neurotropin-3, and neurotropin 4/5.
  • the dosage level of other neurotrophic drugs will depend upon the factors previously stated and the neurotrophic effectiveness of the drug combination.
  • the neurotrophic compounds of this invention can be periodically administered to a patient undergoing treatment for neurological disorders or for other reasons in which it is desirable to stimulate neuronal regeneration and growth, such as in various peripheral neuropathic and neurological disorders relating to neurodegeneration.
  • the compounds of this invention can also be administered to mammals other than humans for treatment of various mammalian neurological disorders.
  • the present invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising: (i) an effective amount of a compound of the present invention; and (ii) a pharmaceutically acceptable carrier.
  • such pharmaceutical composition is effective for effecting a neuronal activity, for treating neurodegenerative diseases, neurological disorders, and nerve damage, or for promoting nerve growth in an animal.
  • reaction mixture was diluted with ether (100 mL) and washed with saturated NaHC0 3 , water and brine.
  • the organic phase was dried, concentrated and chromatographed, eluting with 5:1 CH 2 Cl 2 :EtOAc to obtain
  • Example 1 The method of Example 1 was utilized to prepare 2- ( ⁇ l-oxo-6-phenyl Jhexyl) ( 2S) -1- ( 3 , 3-dimethyl-l , 2- dioxopentyl) piperidine (17), utilizing 2- (ethoxy carboxylate) N-benzylpiperidine and l-chloro-5-phenyl pentane as the starting materials.
  • the major product (85% of the mixture) was the product of aryl coupling to the terminus of the C-C double bond, 3, 3-dimethyl-l- [2- (5- (3-pyridyl) pent-4- enoyl) pyrrolidinyl] pentane-1, 2-dione; the minor product was the product of coupling at the more substituted carbon.
  • the overall yield of the desired product was 480 mg (75%) .
  • Example 4 The method of Example 4 was utilized to prepare 3, 3-dimethyl-l- (2-pent-4-enoylpyrrolidinyl) pentane-1, 2- dione .
  • (25) -1- ( 1 , 2-dioxo-3, 3-dimethylpentyl) -2 - pyrrolidine-carboxylic acid A mixture of methyl (25)- l- ( l , 2-dioxo- 3 , 3-dimethylpentyl ) -2- pyrrolidinecarboxylate (2.10 g; 8.23 mmol), 1 N LiOH (15 ml) , and methanol (50 ml) was stirred at 0°C for 30 minutes and at room temperature overnight. The mixture was acidified to pH 1 with 1 N HCl, diluted with water, and extracted into 100 ml of methylene chloride.
  • Methyl 1- (1, 2-dioxo-2-methoxyethyl) -2-piperidine- carboxylate .
  • a solution of methyl pipecolate hydrochloride (8.50 g; 47.31 mmol) in dry methylene chloride (100 ml) was cooled to 0°C and treated with triethylamine (10.5 g; 103 mmol; 2.1 eq) .
  • a solution of methyl oxalyl chloride (8.50 g; 69.4 mmol) in methylene chloride (75 ml) was added dropwise. The resulting mixture was stirred at 0°C for 1.5 hours.
  • a patient is suffering from a condition or disorder requiring stimulation of damaged neurons, promotion of neuronal regeneration, prevention of neurodegeneration, or treatment of a neurological disorder; wherein the neurological disorder is selected from the group consisting of peripheral neuropathy caused by physical injury or disease state, traumatic injury to the brain, physical damage to the spinal cord, stroke associated with brain damage, and neurological disorders relating to neurodegeneration; and wherein the neurological disorder relating to neurodegeneration is selected from the group consisting of AlzheimerY Disease, HuntingtonY Disease, ParkinsonY Disease, and amyotrophic lateral sclerosis.
  • (25) -3 3-dimethyl-l- [2- (5- (3-pyridyl) pyrrolidinyl] pentane-1, 2-dione, 2- (1-Oxo- 4-phenyl ) -butyl-1- ( 3 , 3-dimethyl-l , 2 - dioxobutyl) pyrrolidine, (2S)-3, 3-dimethyl-l- [2- (5- (4- hydroxyphenyl) pentanoyl) pyrrolidinyl] pentane-1, 2-dione, or 2- ( ⁇ l-oxo-6-phenyl ⁇ -hexyl) (2S) -1- (3, 3-dimethyl-l, 2- dioxopentyl) piperidine, or a pharmaceutical composition comprising the same, may be administered to the patient. Protection from or recovery from the effects of the described condition (s) or disorder (s) is expected to occur following treatment.
  • the compounds of the present invention have an affinity for the FK506 binding protein, particularly FKBP12.
  • the inhibition of the prolyl peptidyl cis-trans isomerase activity of FKBP may be measured as an indicator of this affinity and as a possible indicator of neurotrophic activity.
  • the cis-trans isomerization of an alanine-proline bond in a model substrate, N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide is monitored spectrophotometrically in a chymotrypsin- coupled assay, which releases para-nitroanilide from the trans form of the substrate.
  • the inhibition of this reaction caused by the addition of different concentrations of inhibitor is determined, and the data is analyzed as a change in first-order rate constant as a function of inhibitor concentration to yield the apparent K values.
  • a plastic cuvette In a plastic cuvette are added 950 ml of ice cold assay buffer (25 mM HEPES, pH 7.8, 100 mM NaCl), 10 ml of FKBP (2.5 mM in 10 mM Tris-Cl pH 7.5, 100 mM NaCl, 1 mM dithiothreitol), 25 ml of chymotrypsin (50 mg/ml in 1 mM HCl) and 10 ml of test compound at various concentrations in dimethyl sulfoxide.
  • the reaction is initiated by the addition of 5 ml of substrate (succinyl-Ala-Phe-Pro-Phe-para-nitroanilide, 5 mg/ml in 2.35 mM LiCl in trifluoroethanol) .
  • the absorbance at 390 nm versus time is monitored for 90 seconds using a spectrophotometer and the rate constants are determined from the absorbance versus time data files.
  • the neurotrophic effects of the FKBP inhibitor compounds were demonstrated by evaluating the ability of the compounds to promote neurite outgrowth in cultured chick sensory neurons from dorsal root ganglia.
  • Dorsal root ganglia were dissected from chick embryos of ten day gestation.
  • Whole ganglion explants were cultured on thin layer Matrigel-coated 12 well plates with Liebovitz L15 plus high glucose media supplemented with 2 mM glutamine and 10% fetal calf serum, and also containing 10 ⁇ M cytosine ⁇ -D arabinofuranoside (Ara C) at 37°C in an environment containing 5% C0 2 .
  • the DRGs were treated with various concentrations of nerve growth factor, immunophilin ligands or combinations of NFG plus drugs. Forty-eight hours after drug treatment, the ganglia were visualized under phase contrast or Hoffman Modulation contrast with a Zeiss Axiovert inverted microscope. Photomicrographs of the explants were made, and neurite outgrowth was quantitated. Neurites longer than the DRG diameter were counted as positive, with total number of neurites quantitated per each experimental condition. Three to four DRGs are cultured per well, and each treatment was performed in duplicate.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention relates to neurotrophic, low molecular weight, small molecule heterocyclic ketone and thioester compounds, compositions containing the same, and the use of such compounds for treating neurological disorders, including physically damaged nerves and neurodegenerative diseases.

Description

HETEROCYCLIC KETONE AND THIOESTER COMPOUNDS AND USES
This application is a continuation-in-part of U.S. Patent Application Serial No. 08/904,461, filed August 1, 1997, which is in turn a continuation-in-part of U.S. Patent Application No. 08/721,765, filed September 25, 1996, now U.S. Patent No. 5,786,378, the entire contents of which are considered a part of this application and are hereby incorporated by reference.
BACKGROUND OF THE INVENTION
This invention relates to neurotrophic, low molecular weight, small molecule heterocyclic ketone and thioester compounds, and their use for effecting neuronal activities in animals, including treating neurological disorders.
It has been found that picomolar concentrations of an immunosuppressant, such as FK506 or rapamycin, stimulates neurite outgrowth in PC12 cells and sensory neurons, namely dorsal root ganglion cells (DRGs) . Lyons et al., Proc . of Na tl . Acad. Sci . , 1994, vol. 91, pp. 3191-3195. In whole animal experiments, FK506 has been shown to stimulate nerve regeneration following facial nerve injury and results in functional recovery in animals with sciatic nerve lesions. Studies have demonstrated that neurodegenerative disorders, such as senile dementia of the Alzheimer's type (SDAT or Alzheimer's disease), Parkinson's disease and amyotrophic lateral sclerosis (ALS) , may occur due to the loss, or decreased availability, of a neurotrophic substance specific for a particular population of neurons affected in the disorder. Several neurotrophic factors affecting specific neuronal populations in the central nervous system have been identified. For example, it has been hypothesized that
Alzheimer's disease results from a decrease or loss of nerve growth factor (NGF) . It has thus been proposed to treat SDAT patients with exogenous nerve growth factor or other neurotrophic proteins, such as brain derived growth factor, glial derived growth factor, ciliary neurotrophic factor and neurόtropin-3, to increase the survival of degenerating neuronal populations.
Clinical application of these proteins in various neurological disease states is hampered by difficulties in the delivery and bioavailability of large proteins to nervous system targets. By contrast, immunosuppressant drugs with neurotrophic activity are relatively small and display excellent bioavailability and specificity. However, when administered chronically, immunosuppressants exhibit a number of potentially serious side effects, including nephrotoxicity, such as impairment of glomerular filtration and irreversible interstitial fibrosis (Kopp et al., J. Am . Soc . Nephrol . , 1991, 1:162); neurological deficits, such as involuntary tremors, or non-specific cerebral angina, such as non-localized headaches (De Groen et al., N. Engl . J. Med. , 1987, 317:861); and vascular hypertension, with complications resulting therefrom (Kahan et al., N. Engl . J. Med. , 1989, 321:1725).
To avoid the drawbacks associated with use of large molecule proteins and/or immunosuppressants, the present invention provides small molecule compounds for enhancing neurite outgrowth, and promoting neuronal growth and regeneration in various neuropathological situations where neuronal repair can be facilitated, including: peripheral nerve damage caused by physical injury or disease state such as diabetes; physical damage to the central nervous system (spinal cord and brain) ; brain damage associated with stroke; and neurological disorders relating to neurodegeneration, such as Parkinson's disease, HuntingtonY Disease, SDAT (Alzheimer's disease) and amyotrophic lateral sclerosis (ALS) .
SUMMARY OF THE INVENTION
The present invention relates to neurotrophic, low molecular weight, small molecule heterocyclic ketone or thioester compounds. In a preferred embodiment, the compounds are non-immunosuppressive . In another preferred embodiment, the compounds of the present invention have an affinity for FKBP-type immunophilins, such as FKBP12; and affinity binding or interaction may inhibit the prolyl-peptidyl cis-trans isomerase, or rotamase, activity of the binding protein.
The present invention also relates to a pharmaceutical composition comprising:
(i) an effective amount of a neurotrophic, low molecular weight, small molecule heterocyclic ketone or thioester compound; and (ii) a pharmaceutically acceptable carrier. The present invention further relates to a method of effecting a neuronal activity in an animal, comprising administering to said animal an effective amount of a neurotrophic, low molecular weight, small molecule heterocyclic ketone or thioester compound.
Specifically, the present invention relates to a compound of formula II:
Figure imgf000005_0001
or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein: n is 1 or 2; X is 0 or S;
Z is selected from the group consisting of S, CH2, CHRi, CRXR2, and a bond;
Rx, R2, and R3 are independently selected from the group consisting of CYCs straight or branched chain alkyl, C2-C5 straight or branched chain alkenyl, and Ar, wherein said Rl r R2, or R3 is unsubstituted or substituted with one or more halo, trifluoromethyl, nitro, Cι_-C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, hydroxy, CYC,, alkoxy, C2-C4 alkenyloxy, phenoxy, benzyloxy, amino, or Ar;
R4 is selected from the group consisting of Ci-Cg straight or branched chain alkyl, C2-C9 straight or branched chain alkenyl, C3-C8 cycloalkyl, C5-C7 cycloalkenyl, and Ar; and
Ar is aryl.
The present invention also relates to a pharmaceutical composition comprising:
(i) an effective amount of the compound of formula II; and
(ii) a pharmaceutically acceptable carrier.
The present invention further relates to a method of effecting a neuronal activity in an animal, comprising administering to said animal an effective amount of a compound of formula II.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1(A) is a representative photomicrograph of untreated sensory neurons. FIG. 1(B) is a representative photomicrograph of compound 1 (10 pM) promoting neurite outgrowth in sensory neurons.
FIG. 1(C) is a representative photomicrograph of compound 1 (1 nM) promoting neurite outgrowth in sensory neurons. FIG. 1(D) is a representative photomicrograph of compound 1 (1 μM) promoting neurite outgrowth in sensory neurons .
FIG. 2(A) is a representative photomicrograph of untreated sensory neurons.
FIG. 2(B) is a representative photomicrograph of a related compound, 2-Phenyl-l-ethyl (25) -1- (3, 3-dimethyl- 1, 2-dioxopentyl) -2-pyrrolidinecarbothioate, (10 pM) promoting neurite outgrowth in sensory neurons. FIG. 2(C) is a representative photomicrograph of a related compound, 2-Phenyl-l-ethyl (2S) -1- (3, 3-dimethyl- 1, 2-dioxopentyl) -2-pyrrolidinecarbothioate, (1 nM) promoting neurite outgrowth in sensory neurons.
FIG. 2(D) is a representative photomicrograph of a related compound, 2-Phenyl-l-ethyl (25) -1- ( 3, 3-dimethyl- 1, 2-dioxopentyl) -2-pyrrolidinecarbothioate, (100 nM) promoting neurite outgrowth in sensory neurons.
FIG. 3(A) is a representative photomicrograph of untreated sensory neurons. FIG. 3(B) is a representative photomicrograph of a related compound, 2-Phenyl-l-ethyl 1- (3, 3-dimethyl-l , 2- dioxopentyl) -2-piperidinecarbothioate, (10 pM) promoting neurite outgrowth in sensory neurons .
FIG. 3(C) is a representative photomicrograph of a related compound, 2-Phenyl-l-ethyl 1- (3, 3-dimethyl-l, 2- dioxopentyl) -2-piperidinecarbothioate, (1 nM) promoting neurite outgrowth in sensory neurons.
FIG. 3(D) is a representative photomicrograph of a related compound, 2-Phenyl-l-ethyl 1- (3, 3-dimethyl-l, 2- dioxopentyl) -2-piperidinecarbothioate, (100 nM) promoting neurite outgrowth in sensory neurons.
FIG. 4 presents quantitation for the recovery of TH-positive dopaminergic neurons in the striatum of animals receiving compound 1 and related compounds. DETAILED DESCRIPTION OF THE INVENTION Definitions
"Alkenyl" means a branched or unbranched unsaturated hydrocarbon chain comprising a designated number of carbon atoms. For example, C2-C6 straight or branched alkenyl hydrocarbon chain contains 2 to 6 carbon atoms having at least one double bond, and includes but is not limited to substituents such as ethenyl, propenyl, iso-propenyl, butenyl, iso-butenyl, tert-butenyl, n-pentenyl, n-hexenyl, and the like. It is also contemplated as within the scope of the present invention that "alkenyl" may also refer to an unsaturated hydrocarbon chain wherein any of the carbon atoms of said alkenyl are optionally replaced with 0, NH, S, or S02. For example, carbon 2 of 4-pentene can be replaced with 0 to form (2-propene) oxymethyl .
"Alkoxy" refers to the group -OR wherein R is alkyl as herein defined. Preferably, R is a branched or unbranched saturated hydrocarbon chain containing 1 to 6 carbon atoms.
"Alkyl" means a branched or unbranched saturated hydrocarbon chain comprising a designated number of carbon atoms. For example, Ci-Cg straight or branched alkyl hydrocarbon chain contains 1 to 6 carbon atoms, and includes but is not limited to substituents such as methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert-butyl, n-pentyl, n-hexyl, and the like. It is also contemplated as within the scope of the present invention that "alkyl" may also refer to a hydrocarbon chain wherein any of the carbon atoms of said alkyl are optionally replaced with 0, NH, S, or S02. For example, carbon 2 of n-pentyl can be replaced with 0 to form propyloxymethyl .
Throughout this application, "R" or "Rn", where n is a number, is used to designate various substituents. These R groups are independently selected. Thus, for example, the fact that R, may be a branched alkyl in one context does not require that Rx be the same branched alkyl, and does not prohibit that Rx be, for example, a straight chain alkenyl in another context in the same molecule. It is intended that all "Rn" are selected independently of all other "Rn", whether or not the term "independently selected" is used.
"Aryl" or "aromatic" refers to an aromatic carbocyclic or heterocyclic group having a single ring, for example a phenyl ring; multiple rings, for example biphenyl; or multiple condensed rings in which at least one ring is aromatic, for example naphthyl, 1,2,3,4- tetrahydronaphthyl, anthryl, or phenanthryl . The ring(s) of an aryl moiety can be unsubstituted or substituted with one or more substituents including, but not limited to, halo, hydroxyl, nitro, trifluoromethyl, straight or branched chain alkyl or alkenyl, C1-C4 alkoxy, Cx-C4 alkenyloxy, phenoxy, benzyloxy, or amino; a heterocyclic ring may contain 1-6 heteroatom (s) selected from the group consisting of 0, N, and S. The substituents attached to a phenyl ring portion of an aryl moiety in the compounds of the invention may be configured in the ortho-, meta-, or para- orientation (s) , with the para- orientation being preferred.
Examples of typical aryl moieties included in the scope of the present invention may include, but are not limited to, the following:
Figure imgf000010_0001
It should be kept in mind that, throughout this application, "Ar" or "Arn", where n is a number, is used to designate various substituents. As indicated throughout, these Ar groups are independently selected. Thus, for example, the fact that Ar may be phenyl in one context does not require that Ar be phenyl, nor prohibit that Ar be, for example, pyridyl in another context in the same molecule. It is intended that all "Ar" are selected independently of all other "Ar", whether or not the term "independently selected" is used.
"Carbocycle" or "carbocyclic" refers to an organic cyclic moiety in which the cyclic skeleton is comprised of only carbon atoms, whereas the term "heterocycle" or "heterocyclic" refers to an organic cyclic moiety in which the cyclic skeleton contains one or more heteroatoms selected from nitrogen, oxygen, or sulfur, and which may or may not include carbon atoms . The term "carbocycle" refers to a carbocyclic moiety containing the indicated number of carbon atoms. The term "C3-C8 cycloalkyl", therefore, refers to an organic cyclic substituent in which three to eight carbon atoms form a three, four, five, six, seven, or eight-membered ring, including, for example, a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl ring .
"Carbocyclic" or "heterocyclic" each includes within its scope a single ring system, multiple fused rings (for example, bicyclic, tricyclic, or other similar bridged ring systems or substituents, e.g. adamantyl) or multiple condensed ring systems. One skilled in the art, therefore, will appreciate that in the context of the present invention, a cyclic structure may comprise bi-, or tri-, or multiple condensed rings, bridged ring systems, or combinations thereof.
"Halo" refers to fluoro, chloro, bromo or iodo, unless otherwise indicated.
"Heterocycle" or "heterocyclic", refers to a saturated, unsaturated, or aromatic carbocyclic group having a single ring, multiple fused rings (for example, bicyclic, tricyclic, or other similar bridged ring systems or substituents), or multiple condensed rings, and having at least one heteroatom such as nitrogen, oxygen, or sulfur within at least one of the rings. This term also includes "Heteroaryl," which refers to a heterocycle in which at least one ring is aromatic. Any heterocyclic or heteroaryl group can be unsubstituted or optionally substituted with one or more groups, as defined above. Further, bi- or tricyclic heteroaryl moieties may comprise at least one ring which is either completely • or partially saturated.
As one skilled in the art will appreciate, such heterocyclic moieties may exist in several isomeric forms, all of which are encompassed by the present invention. For example, a 1, 3, 5-triazine moiety is isomeric to a 1, 2, -triazine group. Such positional isomers are to be considered within the scope of the present invention. Likewise, the heterocyclic or heteroaryl groups can be bonded to other moieties in the compounds of the present invention. The point (s) of attachment to these other moieties is not to be construed as limiting on the scope of the invention. Thus, by way of example, a pyridyl moiety may be bound to other groups through the 2-, 3-, or 4-position of the pyridyl group. All such configurations are to be construed as within the scope of the present invention. Examples of heterocyclic or heteroaryl moieties included in the scope of the present invention may include, but are not limited to, the following:
Figure imgf000012_0001
000000
Figure imgf000012_0002
I
11
"Isomers" are different compounds that have the same molecular formula. "Stereoisomers" are isomers that differ only in the way the atoms are arranged in space. "Enantiomers" are a pair of stereoisomers that are non-superimposable mirror images of each other. "Diastereoisomers" are stereoisomers which are not mirror images of each other. "Racemic mixture" means a mixture containing equal parts of individual enantiomers. "Non-racemic mixture" is a mixture containing unequal parts of individual enantiomers or stereoisomers .
"Low molecular weight, small molecule compounds" include, without limitation, molecules which are smaller in size, molecular weight, or both in relation to the compounds Rapamycin, Cyclosporin, and FK506.
"Neurotrophic" includes without limitation the ability to stimulate neuronal regeneration or growth, the ability to prevent or treat neurodegeneration, or both. "Non-immunosuppressive" refers to the inability of the compounds of the present invention to suppress an immune response when compared to a control such as FK506 or cyclosporin A. Assays for determining immunosuppression are well known to those of ordinary skill in the art. Specific, non-limiting examples of well known assays include PMA and OKT3, wherein mitogens are used to stimulate proliferation of human peripheral blood lymphocytes (PBC) and the tested compounds are evaluated on their ability to inhibit such proliferation.
"Pharmaceutically acceptable carrier" refers to any carrier, diluent, excipient, suspending agent, lubricating agent, adjuvant, vehicle, delivery system, emulsifier, disintegrant , absorbant, preservative, surfactant, colorant, flavorant, or sweetener. For these purposes, the compounds of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir in dosage formulations containing conventional non-toxic pharmaceutically- acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous, intravenous, intramuscular, intraperitoneally, intrathecally, intraventricularly, intrasternal, and intracranial injection or infusion techniques.
"Pharmaceutically acceptable salt", refers to an organic or inorganic salt which is useful in the treatment of a warm-blooded animal in need thereof. Such salts can be acid or basic addition salts, depending on the nature of the inventive compound to be used.
In the case of an acidic moiety in an inventive compound, a salt may be formed by treatment of the inventive compound with a basic compound, particularly an inorganic base. Preferred inorganic salts are those formed with alkali and alkaline earth metals such as lithium, sodium, potassium, barium, and calcium. Preferred organic base salts include, for example, ammonium, dibenzylammonium, benzylammonium, 2- hydroxyethylammonium, bis (2-hydroxyethyl ) ammonium, phenylethylbenzylamine, dibenzyl-ethylenediamine, and like salts. Other salts of acidic moieties may include, for example, those salts formed with procaine, quinine and N-methylglucosamine, plus salts formed with basic amino acids such as glycine, ornithine, histidine, phenylglycine, lysine and arginine. Other suitable base salts, esters, or solvates include magnesium salts; salts with organic bases, such as dicyclohexylamine salts; and N-methyl-D-glucamine . An especially preferred salt is a sodium or potassium salt of an inventive compound.
With respect to basic moieties, a salt is formed by the treatment of the desired inventive compound with an acidic compound, particularly an inorganic acid. Preferred inorganic salts of this type may include, for example, hydrochloric, hydrobromic, hydroiodic, sulfuric, phosphoric, or like salts. Preferred organic salts of this type, may include, for example, salts formed with formic, acetic, succinic, citric, lactic, maleic, fumaric, palmitic, cholic, pamoic, mucic, d- glutamic, d-camphoric, glutaric, glycolic, phthalic, tartaric, lauric, stearic, salicyclic, methanesulfonic, benzenesulfonic, para-toluenesulfonic, sorbic, puric, benzoic, cinnamic, and like organic acids. Other suitable acids are adipate, alginate, aspartate, benzenesulfonate, bisulfate, butyrate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, 2-hydroxyethanes- ulfonate, methanesulfonate, naphthylate, 2- naphthalenesulfonate, nicotinate, oxalate, thiocyanate, tosylate, and undecanoate. An especially preferred salt of this type is a hydrochloride or sulfate salt of the desired inventive compound. Also, the basic nitrogen- containing groups can be quarternized with such agents as: 1) lower alkyl halides, such as methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; 2) dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates; 3) long chain alkyls such as decyl, lauryl, myristyl, and stearyl substituted with one or more halide such as chloride, bromide, and iodide; and 4) aralkyl halides like benzyl and phenethyl bromide and others .
Also encompassed in the scope of the present invention are pharmaceutically acceptable esters of a carboxylic acid or hydroxyl containing group, including a metabolically labile ester or a prodrug form of an inventive compound. A metabolically labile ester is one which may produce, for example, an increase in blood levels and prolong the efficacy of the corresponding non-esterified form of the compound. A prodrug form is one which is not in an active form of the molecule as administered but which becomes therapeutically active after some in vivo activity or biotransformation, such as, for example, metabolism by enzymatic or hydrolytic cleavage. Esters of an inventive compound may include, for example, methyl, ethyl, propyl, and butyl esters, as well as other suitable esters formed between an acidic moiety and a hydroxyl containing moiety. Metabolically labile esters may include, for example, methoxymethyl, ethoxymethyl, iso-propoxymethyl, α-methoxyethyl, and groups such as - ( (C-L-C alkyloxy) ethyl; methoxyethyl, ethoxyethyl, propoxyethyl, and iso-propoxyethyl; 2-oxo- 1, 3-dioxolen-4-ylmethyl groups, such as 5-methyl-2-oxo- 1, 3, dioxolen-4-ylmethyl; C^^ alkylthiomethyl groups, for example, methylthiomethyl, ethylthiomethyl, isopropylthiomethyl; acyloxymethyl groups, for example, pivaloyloxy-methyl, α-acetoxymethyl; ethoxycarbonyl-1- methyl; or α-acyloxy-α-substituted methyl groups, for example α-acetoxyethyl .
Further, the compounds of the invention may exist as crystalline solids which can be crystallized from common solvents such as ethanol, N, N-dimethyl-formamide, water, or the like. Thus, crystalline forms of the compounds of the invention may exist as solvates and/or hydrates of the parent compounds or their pharmaceutically acceptable salts, esters, or solvates. All of such forms likewise are to be construed as falling within the scope of the invention. "Phenyl" refers to any possible isomeric phenyl radical, optionally monosubstituted or multisubstituted with substituents selected from the group consisting of alkyl, alkoxy, hydroxy, halo, and haloalkyl.
"Preventing neurodegeneration" includes (1) the ability to inhibit or prevent neurodegeneration in patients newly diagnosed as having a neurodegenerative disease or at risk of developing a new neurodegenerative disease and (2) the ability to inhibit or prevent further neurodegeneration in patients who are already suffering from, or have symptoms of, a neurodegenerative disease .
"Treating" or "treatment" covers any treatment of a disease, a condition, or both in an animal, particularly a human, and includes: (i) preventing a disease or condition from occurring in a subject which may be predisposed to the disease or condition but has not yet been diagnosed as having it;
(ii) inhibiting a disease or condition, i.e., arresting its development; or
(iii) relieving a disease or condition, i.e., causing regression of the disease or condition.
"Warm-blooded animal" or "animal" includes a mammal, including a member of the human, equine, porcine, bovine, murine, canine, or feline species. In the case of a human, the term "warm-blooded animal" or "animal" may also be referred to as a "patient". Further, as used herein, "a warm blooded animal in need thereof" refers to a warm-blooded animal which is susceptible to a disorder due to genetic or environmental conditions or predispositions. This term also refers to a warm blooded animal which has already suffered some degree of injury or damage because of genetic or environmental conditions to which the animal has been exposed or to which it is or was predisposed. Environmental conditions can include treatment with a therapeutic compound, as well as other types of injury or insult.
Compounds of the Invention
The present invention relates to low molecular weight, small molecule neurotrophic compounds. In a preferred embodiment, the compounds of the present invention do not exert any significant immunosuppressive activity. In another preferred embodiment, the compounds of the present invention may bind to, or otherwise interact with, FKBP-type immunophilins, such as FKBP12; such binding or interaction may inhibit the prolyl-peptidyl cis-trans isomerase, or rotamase, activity of the binding protein.
In another preferred embodiment, the compound of the present invention has a molecular weight no more than about 800 daltons. In a more preferred embodiment, the compound of the present invention has a molecular weight no more than about 500 daltons. In a particularly preferred embodiment, the compound of the present invention has a molecular weight no more than about 330 daltons.
In another preferred embodiment, the compound of the present invention exhibits a Chick Dorsal Root Ganglion Neurite Outgrowth Assay ("DRG") ED50 value which is less than about 10 nM. In a more preferred embodiment, the compound of the present invention exhibits a DRG ED50 value which is less than about 1.0 nM. In a particularly preferred embodiment, the compound of the present invention exhibits a DRG ED50 value which is less than about 0.1 nM.
In another preferred embodiment, the compound of the present invention exhibits an MPTP Assay value which is greater than about 20% recovery of TH-stained dopaminergic neurons. In a more preferred embodiment, the compound of the present invention exhibits an MPTP Assay value which is greater than about 35% recovery of TH-stained dopaminergic neurons. In a particularly preferred embodiment, the compound of the present invention exhibits an MPTP Assay value which is greater than about 50% recovery of TH-stained dopaminergic neurons .
FORMULA I
A preferred embodiment of this invention is a compound of formula I :
Figure imgf000019_0001
or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
A and B, together with the nitrogen and carbon atoms to which they are respectively attached, form a 5- 7 membered saturated or unsaturated heterocyclic ring containing any combination of CH2, 0, S, SO, S02, NH, or NR4 in any chemically stable oxidation state;
X is either 0 or S;
Z is either S, CH2, CHR,_, CRXR2, or a bond;
W and Y are independently 0, S, CH2, or H2;
Rx, R2, and R3 are independently Ci-Cg straight or branched chain alkyl or alkenyl, which is substituted in one or more position (s) with (ArY, (Ar-Y connected by a Ci-Cg straight or branched chain alkyl or alkenyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl connected by a Ci-Cg straight or branched chain alkyl or alkenyl, or Ar2; n is 1 or 2;
R4 is either Cj-Cg straight or branched chain alkyl, C2-C9 straight or branched chain alkenyl, C3-C8 cycloalkyl, C5-C7 cycloalkenyl or Rrl r wherein said alkyl, alkenyl, cycloalkyl or cycloalkenyl is either unsubstituted or substituted in one or more position (s) with Cι~C4 straight or branched chain alkyl or alkenyl, or hydroxyl; and Arx and Ar2 are each, independently, an aryl group.
A preferred embodiment of an aryl group is a mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein the ring is either unsubstituted or substituted in one or more position (s) with halo, hydroxyl, nitro, trifluoromethyl, C^Cg straight or branched chain alkyl or alkenyl, C^C,, alkoxy, Cx-C4 alkenyloxy, phenoxy, benzyloxy, or amino; wherein the individual ring sizes are 5-6 members; and wherein the heterocyclic ring contains 1-6 heteroatom (s) selected from the group consisting of 0, N, and S.
Suitable mono- and bicyclic, carbo- and heterocyclic rings include, without limitation, naphthyl, indolyl, thioindolyl, furyl, thiazolyl, thienyl, pyridyl, quinolinyl, isoquinolinyl, fluorenyl, phenyl, and benzyl.
FORMULA II
Another preferred embodiment of this invention is a compound of formula II:
Figure imgf000020_0001
or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein: n is 1 or 2; X is 0 or S; Z is selected from the group consisting of S, CH2,
CHRi, CR^ and a bond;
Rl r R2, and R3 are independently selected from the group consisting of Ci-Cj straight or branched chain alkyl, C2-C5 straight or branched chain alkenyl, and Ar, wherein said Rl f R2, or R3 is unsubstituted or substituted with one or more halo, trifluorormethyl, nitro, Ci-Cg straight or branched chain alkyl, C2-C5 straight or branched chain alkenyl, hydroxy, Cx-C4 alkoxy, C2-C4 alkenyloxy, phenoxy, benzyloxy, amino, or Ar; R4 is selected from the group consisting of Ci-Cg straight or branched chain alkyl, C2-C9 straight or branched chain alkenyl, C3-C8 cycloalkyl, C5-C7 cycloalkenyl, and Ar; and
Ar is aryl. A preferred embodiment for Ar is phenyl, benzyl, pyridyl, fluorenyl, thioindolyl, or naphthyl, wherein said Ar is unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, trifluoromethyl, hydroxy, nitro, C^Cg straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, Ci-C,, alkoxy, C2-C4 alkenyloxy, phenoxy, benzyloxy, and amino.
A particularly preferred embodiment of Formula II is a compound wherein n is 1, X is 0, Z is CH2, R3 is 3- pyridylpropyl, and R4 is 1, 1-dimethylpropyl .
Another particularly preferred embodiment of Formula II is a compound wherein n is 2 , X is 0, Z is CH2j R3 is 4-phenylbutyl, and R4 is 1, 1-dimethylpropyl .
Another particularly preferred embodiment of Formula II is a compound wherein n is 1, X is 0, Z is CH2ι R3 is 2-phenylethyl, and R4 is tert-butyl.
Another particularly preferred embodiment of Formula II is a compound wherein n is 1, X is 0, Z is CH2/ R3 is 3- ( -hydroxyphenyl) propyl, and R4 is 1,1- dimethylpropyl .
The most preferred embodiments of Formula II are ( 2 S ) -3, 3-dimethyl-l- [2- ( 5- ( 3-pyridyl) pyrrolidinyl] pentane-1, 2-dione; 2- ( { l-oxo-6-phenyl } - hexyl) (2S) -1- (3, 3-dimethyl-l, 2-dioxopentyl) piperidine; 2- (l-Oxo-4-phenyl) -butyl-1- (3, 3-dimethyl-l, 2- dioxobutyl) pyrrolidine; and (2S) -3, 3-dimethyl-l- [2- (5- ( 4-hydroxyphenyl) pentanoyl) pyyrolidinyl ] pentane-1, 2- dione .
Specific examples of the embodiments of Formula II are presented in TABLE I. The molecular weights of the specifically exemplified compounds is between about 330 daltons and about 500 daltons.
Figure imgf000023_0001
TABLE I n X z R3 R4
O CH2 3-Phenylpropyl 1 , l-Dimethylpropyl
O CH2 3-(3-Pyridyl)propyl 1 , l-Dimethylpropyl
O CH2 3-Phenylpropyl tert-Butyl
O CH2 3-(3-Pyridyl)propyl tert-Butyl
O CH2 3-(3-Pyridyl)propyl Cyclohexyl
O CH2 3-(3-Pyridyl)propyl Cyclopentyl
O CH2 3-(3-Pyridyl)propyl Cycloheptyl
O CH2 2-(9-Fluorenyl)ethyl 1 , l-Dimethylpropyl
O S 2-Phenethyl 1 , 1 -Dimethylpropyl
2 O S 2-Phenethyl 1 , l-Dimethylpropyl
O S Methyl(2-thioindole) 1 , l-Dimethylpropyl
O S 2-Phenethyl Cyclohexyl
2 O S 2-Phenethyl tert-Butyl
2 O S 2-Phenethyl Phenyl
1 O CH2 3-(4-Methoxyphenyl)propyl 1 , l-Dimethylpropyl
2 O CH2 4-(4-Methoxyphenyl)butyl 1 , l-Dimethylpropyl
2 O CH2 4-Phenylbutyl 1 , l-Dimethylpropyl
2 O CH2 4-Phenylbutyl Phenyl
2 O CH2 4-Phenylbutyl tert-Butyl
1 s CH2 3-Phenylpropyl 1 , l-Dimethylpropyl
1 s S 2-Phenethyl 1 , l-Dimethylpropyl
2 s CH2 3-Phenylpropyl 1 , l-Dimethylpropyl
2 s S 2-Phenethyl 1 , l-Dimethylpropyl
1 O s 2-Phenethyl Cyclopentyl TABLE I (continued) n X z R3 R4
2 O s 3-Phenylpropyl tert-Butyl
O s 3-Phenylpropyl 1 , l-Dimethylpropyl
O s 3-(3-Pyridyl)propyl 1 , l-Dimethylpropyl
O s 3-Phenylpropyl Cyclohexyl
O s 4-Phenylbutyl Cyclohexyl
O s 4-Phenylbutyl 1 , l-Dimethylpropyl
O s 3-(3-Pyridyl)propyl Cyclohexyl
O s 3,3-Diphenylpropyl 1 , l-Dimethylpropyl
O s 3,3-Diphenylpropyl Cyclohexyl
O s 3-(4-Methoxyphenyl) 1 , l-Dimethylpropyl propyl
2 O s 4-Phenylbutyl tert-Butyl
2 O s 1 ,5-Diphenyl-3-pentyl 1 , l-Dimethylpropyl
2 O s 1 ,5-Diphenyl-3-pentyl Phenyl
2 O s 3-(4-Methoxyphenyl) 1 , l-Dimethylpropyl propyl
2 O s 3-(4-Methoxyphenyl) Phenyl propyl
2 O s 3 -( 1 -Naphthy l)propy 1 1 , l-Dimethylpropyl
1 O s 3 , 3 -Di(4-fluoro)pheny 1- 1 , l-Dimethylpropyl propyl
1 O s 4 , 4-Di(4-fluoro)pheny 1- 1 , l-Dimethylpropyl butyl
1 O s 3 -(1 -Naphthy l)propyl 1 , l-Dimethylpropyl
1 O s 2,2-Diphenylethyl 1 , l-Dimethylpropyl
2 O s 2,2-Diphenylethyl 1 , l-Dimethylpropyl
2 O s 3 ,3-Diphenylpropyl 1 , l-Dimethylpropyl
1 O s 3-(4-{Trifluoromethyl}- 1 , l-Dimethylpropyl phenyl)propyl
1 O s 3-(2-Naphthyl)propyl 1 , l-Dimethylpropyl TABLE I (continued) n X Z R3 R4
2 O s 3-(l-Naphthyl)propyl 1, 1-Dimethylpropyl
1 O s 3-(3-Chloro)phenylpropyl 1 , l-Dimethylpropyl
1 O s 3-(3-{Trifluoromethyl}- 1 , l-Dimethylpropyl phenyl)propyl
1 O s 3-(2-Biphenyl)propyl 1 , l-Dimethylpropyl
1 O s 3-(2-Fluorophenyl)propyl 1 , l-Dimethylpropyl
1 O s 3-(3-Fluorophenyl)propyl 1 , l-Dimethylpropyl
2 O s 4-Phenylbutyl 1 , l-Dimethylpropyl
2 O s 3-Phenylpropyl 1, 1-Dimethylpropyl
1 O s 3-(2-Chloro)phenylpropyl 1 , l-Dimethylpropyl
2 O s 3-(3-Chloro)phenylpropyl 1 , l-Dimethylpropyl
2 O s 3-(2-Fluoro)phenylpropyl 1 , l-Dimethylpropyl
2 O s 3-(3-Fluoro)phenylpropyl 1 , l-Dimethylpropyl
1 O s 3-(3 ,4-Dimethoxyphenyl)- 1 , l-Dimethylpropyl propyl
1 O CH2 3-Phenylpropyl Cyclohexyl
1 O CH2 2-Phenylethyl tert-Butyl
2 O CH2 4-Phenylbutyl Cyclohexyl
2 O CHR, 2-Phenylethyl tert-Butyl
1 O CH2 3,3-Di(4-fluorophenyl)- 1 , l-Dimethylpropyl propyl
2 O CH2 3-Phenylpropyl 1 , l-Dimethylpropyl
1 O CH2 3 -(4-Hydroxypheny l)propyl 1 , l-Dimethylpropyl
1 O bond 3-Phenylpropyl 1 , l-Dimethylpropyl
1 O bond 3-(3-Pyridyl)propyl tert-Butyl
1 O bond 3-(3-Pyridyl)propyl Cyclohexyl
2 O bond 4-(4-Methoxyphenyl)butyl 1 , l-Dimethylpropyl
2 O bond 4-Phenylbutyl 1 , l-Dimethylpropyl
2 O bond 4-Phenylbutyl Phenyl The most preferred examples of the compounds of TABLE I are named as follows:
1 (2S) -3, 3-dimethyl-l- [2- (5-phenylpentanoyl) pyrrolidinyl] pentane-1, 2-dione
2 (2S) -3, 3-dimethyl-l- [2- (5- (3-pyridyl) pyrrolidinyl] pentane-1, 2-dione
3 (2S) -2- ({l-oxo-5-phenyl Ypentyl-1- (3, 3-dimethyl- 1, 2-dioxobutyl) pyrrolidine 9 2-Phenyl-l-ethyl ( 2 S) -1- ( 3 , 3-dimethyl-l , 2- dioxopentyl) -2-pyrrolidinecarbothioate
10 2-Phenyl-l-ethyl 1- (3, 3-dimethyl-l, 2-dioxopentyl) -2-piperidinecarbothioate
11 l-{2-benzo[b] thiophen-3-ylmethylthio ) carbonyl] pyrrolidinyl } -3, 3-dimethylpentane-l, 2-dione
12 2-Phenyl-l-ethyl ( 2 S) -1- ( 2-cyclohexyl-l , 2- dioxoethyl) -2-pyrrolidinecarbothioate
14 2-Phenyl-l-ethyl 1- (2-phenyl-l, 2-dioxoethyl) -2- piperidinecarbothioate 17 2-({l-oxo-6-phenyl Yhexyl) (2S) -1- (3, 3-dimethyl- 1, 2-dioxopentyl) piperidine
24 2-Phenyl-l-ethyl ( 25) -1- ( 1-cyclopentyl-l , 2- dioxoethyl) -2-pyrrolidinecarbothioate
25 3-Phenyl-l-propyl 1- (3, 3-dimethyl-l, 2-dioxobutyl) -2-piperidinecarbothioate
26 3-Phenyl-l-propyl ( 25) -1- ( 3 , 3-dimethyl-l , 2- dioxopentyl) -2-pyrrolidinecarbothioate
27 3- (3-Pyridyl) -1-propyl (25) -1- (3, 3-dimethyl-l, 2- dioxopentyl) -2-pyrrolidinecarbothioate 28 3-Phenyl-l-propyl (2S) -1- ( 2-cyclohexyl-l , 2- dioxoethyl) -2-pyrrolidinecarbothioate
29 4-Phenyl-l-butyl ( 2 S) -1- ( 2-cyclohexyl-l , 2- dioxoethyl) -2-pyrrolidinecarbothioate
30 4-Phenyl-l-butyl ( 2 S) -1- ( 3 , 3-dimethyl-l , 2- dioxopentyl) -2-pyrrolidinecarbothioate 3-(3-Pyridyl)-l-propyl (25) -1- (2-cyclohexyl-l, 2- dioxoethyl) -2-pyrrolidinecarbothioate 3,3-Diphenyl-l-propyl (2S) -1- (3, 3-dimethyl-l, 2- dioxopentyl) -2-pyrrolidinecarbothioate 3,3-Diphenyl-l-propyl (2S) -1- (2-cyclohexyl-l, 2- dioxoethyl) -2-pyrrolidinecarbothioate 3- (para-Methoxyphenyl) -1-propyl (2S) -1- ( 3, 3-dimethyl-l, 2-dioxopentyl) -2-pyrrolidinecarbothioate 4-Phenyl-l-butyl 1- ( 1, 2-dioxo-3, 3-dimethylbutyl) - 2-piperidinecarbothioate 1 , 5-Diphenyl-3-pentyl 1- ( 3 , 3-dimethyl-l , 2- dioxopentyl) -2-piperidinecarbothioate 1, 5-Diphenyl-3-pentyl 1- (2-phenyl-l, 2-dioxoethyl) -2-piperidinecarbothioate 3- (para-Methoxyphenyl) -1-propyl 1- (1, 2-dioxo-3, 3- dimethylpentyl) piperidine-2-carbothioate 3- (para-Methoxyphenyl) -1-propyl 1- (2-phenyl-l, 2- dioxoethyl) piperidine-2-carbothioate 3- (1-Naphthyl) -1-propyl 1- ( 3, 3-dimethyl-l , 2- dioxopentyl) piperidine-2-carbothioate 3, 3-Di (para-fluoro) phenyl-1-propyl (2S) -1- (3, 3-di methyl-1, 2-dioxopentyl) -2-pyrrolidinecarbothioate 4, 4-Di (para-fluorophenyl) butyl 1- (3, 3-dimethyl-2- oxopentanoyl) -2-pyrrolidinecarbothioate 3- (1-Naphthyl) -1-propyl (25) -1- (3, 3-dimethyl-2- oxopentanoyl) -2-pyrrolidinecarbothioate 2,2-Diphenylethyl ( 2 S) - 1- ( 3 , 3-dimethyl-2- oxopentanoyl) -2-pyrrolidinecarbothioate 2,2-Diphenylethyl ( 2 S) -1- ( 3 , 3-dimethyl-2- oxopentanoyl) -2-piperidinecarbothioate 3,3-Diphenylpropyl 1- (3, 3-dimethyl-2-oxopentanoyl) - 2-piperidinecarbothioate 3- [4- (Trifluoromethyl) phenyl] propyl (2S)-l-(3,3- dimethyl-2-oxopentanoyl) -2-pyrrolidinecarbothioate 3- (2-Naphthyl) propyl (25) -1- ( 3, 3-dimethyl-2- oxopentanoyl) -2-pyrrolidinecarbothioate 3- (1-Naphthyl) -1-propyl 1- ( 3 , 3-dimethyl-2- oxopentanoyl) -2-piperidinecarbothioate 3- (3-Chlorophenyl) propyl (25) -1- ( 3, 3-dimethyl-2- oxopentanoyl) -2-pyrrolidinecarbothioate 3- [3- (Trifluoromethyl) phenyl] propyl (2S)-l-(3,3- dimethyl-2-oxopentanoyl) -2-pyrrolidinecarbothioate 3- (2-Biphenyl) propyl (25) -1- ( 3, 3-dimethyl-2- oxopentanoyl) -2-pyrrolidinecarbothioate 3- (2-Fluorophenyl) propyl (2S) -1- (3, 3-dimethyl-2- oxopentanoyl) -2-pyrrolidinecarbothioate 3- (3-Fluorophenyl) propyl (25) -1- (3, 3-dimethyl-2- oxopentanoyl) -2-pyrrolidinecarbothioate 4-Phenylbutyl 1- (3, 3-dimethyl-2-oxopentanoyl) -2- piperidinecarbothioate 3-Phenylpropyl 1- (3, 3-dimethyl-2-oxopentanoyl) -2- piperidinecarbothioate 3- (2-Chlorophenyl) propyl (25) -1- (3, 3-dimethyl-2- oxopentanoyl) -2-pyrrolidinecarbothioate 3- (3-Chlorophenyl) -1-propyl 1- (3, 3-dimethyl-2- oxopentanoyl) -2-piperidinecarbothioate 3- (2-Fluorophenyl) propyl 1- ( 3 , 3-dimethyl-2- oxopentanoyl) -2-piperidinecarbothioate 3- ( 3-Fluorophenyl ) propyl 1- ( 3 , 3-dimethyl-2- oxopentanoyl) -2-piperidinecarbothioate 3- (3, 4-Dimethoxyphenyl) propyl (2S) -1- (3, 3-di- methy1-2-oxopentanoyl) -2-pyrrolidinecarbothioate (2S) -2- ( { l-Oxo-5-phenyl}pentyl-l- (2-Cyclohexyl-l, 2- dioxoethyl) pyrrolidine 2- (1-Oxo- -phenyl) -butyl-1- (3, 3-dimethyl-l, 2- dioxobutyl) pyrrolidine 2- (1-Oxo-6 -phenyl) -hexyl-l-(2-Cyclohexyl-l,2- dioxoethyl) piperidine 2- ({l-Oxo-[2-{2'-phenyl}ethyl] -4-phenyl } -butyl-1- (3, 3-dimethyl-l, 2-dioxobutyl) piperidine
66 (25)-2-[5, 5-di ( 4 -Fluorophenyl ) pentanoyl ] -1- (3, 3 dimethyl-1, 2-pentanedione) pyrrolidine
67 3, 3-Dimethyl-l- [2- (5-phenylpentanoyl) piperidino] - 1, 2-pentanedione
68 (25) -3, 3-dimethyl-l- [2- (5- (4-hydroxyphenyl) pentanoyl) pyyrolidinyl] penatane-1, 2-dione
FORMULA III
Another preferred embodiment is a compound of formula III:
Figure imgf000029_0001
or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
A, B, and C are independently CH2, 0, S, SO, S02, NH, or NR4;
X is 0 or S;
Z is S, CH2, CHRX, or CR^;
Rl f R2, and R3 are independently C^Cg straight or branched chain alkyl or alkenyl, which is substituted in one or more position (s) with (ArY, (Ar n connected by a Ci-Cg straight or branched chain alkyl or alkenyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl connected by a C^Cg straight or branched chain alkyl or alkenyl, Ar2, or a combination thereof; n is 1 or 2;
R4 is either straight or branched chain alkyl or alkenyl, C3-C8 cycloalkyl, C5-C7 cycloalkenyl or Ar:, wherein said alkyl, alkenyl, cycloalkyl or cycloalkenyl is either unsubstituted or substituted in one or more position (s) with C^C,, straight or branched chain alkyl or alkenyl, hydroxyl, or a combination thereof; and r! and Ar2 are independently a mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein the ring is either unsubstituted or substituted in one to three position (s) with halo, hydroxyl, nitro, trifluoromethyl, Ci-Cg straight or branched chain alkyl or alkenyl, CΪ-C,, alkoxy, C^C, alkenyloxy, phenoxy, benzyloxy, amino or a combination thereof; wherein the individual ring sizes are 5-6 members; and wherein the heterocyclic ring contains 1-6 heteroatom ( s) selected from the group consisting of 0, N, S, and a combination thereof.
Particularly preferred compounds of formula III are presented in TABLE II.
Figure imgf000030_0001
TABLE II
No. A B C X R R.
75 CH2 S CH2 O S 2-phenethyl 1 , l-Dimethylpropyl
76 CH2 s CH2 O CH2 3-phenylpropyl 1 , l-Dimethylpropyl
77 CH2 CH2 NH O S 2-phenethyl 1 , l-Dimethylpropyl
78 CH2 s CH2 s S 2-phenethyl 1 , l-Dimethylpropyl
FORMULA IV
A further preferred embodiment of this invention is a compound of formula IV:
Figure imgf000031_0001
or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein: A, B, C, and D are independently CH2, 0, S, SO, S02, NH, or NR4;
X is 0 or S;
Figure imgf000031_0002
Rτ_, R2, and R3 are independently C^Cg straight or branched chain alkyl or alkenyl, which is substituted in one or more position (s) with (ArY, (ArY connected by a Ci-Cg straight or branched chain alkyl or alkenyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl connected by a C^Cg straight or branched chain alkyl or alkenyl, Ar2, or a combination thereof; n is 1 or 2;
R4 is either Cτ_-C9 straight or branched chain alkyl or alkenyl, C3-C8 cycloalkyl, C5-C7 cycloalkenyl or Arx, wherein said alkyl, alkenyl, cycloalkyl or cycloalkenyl is either unsubstituted or substituted in one or more position (s) with Ci-C,) straight or branched chain alkyl or alkenyl, hydroxyl, or a combination thereof; and
Ar! and Ar2 are independently a mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein the ring is either unsubstituted or substituted in one to three position (s) with halo, hydroxyl, nitro, trifluoromethyl, Ci-Cg straight or branched chain alkyl or alkenyl, C1-C4 alkoxy, C^C,, alkenyloxy, phenoxy, benzyloxy, amino, or a combination thereof; wherein the individual ring sizes are 5-6 members; and wherein the heterocyclic ring contains 1-6 heteroatom (s) selected from the group consisting of 0, N, S, and a combination thereof.
Particularly preferred compounds of formula IV are presented in TABLE III.
Figure imgf000032_0001
TABLE III
No. A B C D X Z R3 R.
79 CH2 CH2 O CH2 O CH2 3-phenylpropyl 1 , l-Dimethylpropyl
80 CH2 CH2 O CH2 O S 2-phenethyl 1 , l-Dimethylpropyl
81 CH2 CH2 S CH2 O CH2 3-phenylpropyl 1 , l-Dimethylpropyl
82 CH, CH, CH, O S 2-phenethyl 1 , l-Dimethylpropyl
The compounds of this invention possess at least one asymmetric center and thus can be produced as mixtures of stereoisomers or as individual R- and S- stereoisomers . The individual enantiomers may be obtained by using an optically active starting material, by resolving a racemic or non-racemic mixture of an intermediate at some appropriate stage of the synthesis, or by resolving a compound of the present invention. It is understood that the individual R- and S- stereoisomers as well as mixtures (racemic and non- racemic) of stereoisomers are encompassed by this invention. The S-stereoisomer is most preferred.
Synthesis of Pyrrolidine Derivatives
The compounds of formulas I to IV may be prepared by a variety of synthetic sequences that utilize established chemical transformations. The general pathway to the present compounds is described in Scheme I. Starting compounds may be reacted with a variety of alkenyl magnesium halides to form olefin intermediates (1) , which are in turn reacted sequentially with trifluroacetic acid, then methyl oxalyl chloride and triethylamine. The resulting oxamates (2) may be reacted with a variety of carbon nucleophiles, such as Rj-MgCl, to obtain further olefin intermediates (3) . These intermediates are then reacted with a variety of organohalogen compounds, such as R2-Br, to produce product (4) , which is hydrogenated to produce compounds of the present invention (5) .
SCHEME I
Figure imgf000033_0001
Figure imgf000033_0002
Methods of Using the Compounds of the Invention
The present invention further relates to the use of a compound of the present invention in the preparation of a medicament for effecting a neuronal activity in an animal .
Further, the present invention relates to a method of effecting a neuronal activity in an animal, comprising administering to said animal a neurotrophically effective amount of a compound of the present invention.
As neurotrophic agents, the compounds of this invention can be periodically administered to a patient undergoing treatment for neurological disorders or for other reasons in which it is desirable to stimulate neuronal regeneration and growth, such as in various peripheral neuropathic and neurological disorders relating to neurodegeneration. The compounds of this invention can also be administered to mammals other than humans for treatment of various mammalian neurological disorders.
The novel compounds of the present invention possess an excellent degree of neurotrophic activity. This activity is useful in the stimulation of damaged neurons, the promotion of neuronal regeneration, the prevention of neurodegeneration, and in the treatment of several neurological disorders known to be associated with neuronal degeneration and peripheral neuropathies. The neurological disorders that may be treated include but are not limited to: trigeminal neuralgia, glossopharyngeal neuralgia, Bell's Palsy, myasthenia gravis, muscular dystrophy, amyotrophic lateral sclerosis, progressive muscular atrophy, progressive bulbar inherited muscular atrophy, herniated, ruptured or prolapsed invertebrate disk syndromes, cervical spondylosis, plexus disorders, thoracic outlet destruction syndromes, peripheral neuropathies such as those caused by lead, dapsone, ticks, prophyria, Gullain-Barre syndrome, Alzheimer's disease, Huntington' s Disease, or Parkinson's disease. For these purposes, the compounds may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally, or via an implanted reservoir in dosage formulations containing conventional non-toxic pharmaceutically- acceptable carriers, adjuvants, and vehicles. The term parenteral as used herein includes subcutaneous, intravenous, intramuscular, intraperitoneally, intrathecally, intraventricularly, intrasternal, and intracranial injection or infusion techniques. To be effective therapeutically as central nervous system targets, the compounds should readily penetrate the blood-brain barrier when peripherally administered. Compounds which cannot penetrate the blood-brain barrier can be effectively administered by an intraventricular route.
The compounds may be administered in the form of sterile injectable preparations, for example, as sterile injectable aqueous or oleaginous suspensions. These suspensions, may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparations may also be sterile injectable solutions or suspensions in non-toxic parenterally-acceptable diluents or solvents, for example, as solutions in 1,3- butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as solvents or suspending mediums. For this purpose, any bland fixed oil such as a synthetic mono- or di- glyceride may be employed. Fatty acids such as oleic acid and its glyceride rierivatives, including olive oil and castor oil, especially in their polyoxyethylated versions, are useful in the preparation of injectables. These oil solutions or suspensions may also contain long-chain alcohol diluents or dispersants.
Additionally, the compounds may be administered orally in the form of capsules, tablets, aqueous suspensions, or solutions. Tablets may contain carriers such as lactose and corn starch, and/or lubricating agents such as magnesium stearate. Capsules may contain diluents including lactose and dried corn starch. Aqueous suspensions may contain emulsifying and suspending agents combined with the active ingredient. The oral dosage forms may further contain sweetening, flavoring, coloring agents, or combinations thereof.
The compounds may also be administered rectally in the form of suppositories. These compositions can be prepared by mixing the drug with a suitable non- irritating excipient which is solid at room temperature, but liquid at rectal temperature and, therefore, will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax, and polyethylene glycols. Furthermore, the compounds may be administered topically, especially when the conditions addressed for treatment involve areas or organs readily accessible by topical application, including neurological disorders of the eye, the skin, or the lower intestinal tract. Suitable topical formulations can be readily prepared for each of these areas.
For topical application to the eye, or ophthalmic use, the compounds can be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as a solution in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, the compounds may be formulated into ointments, such as petrolatum, for ophthalmic use.
For topical application to the skin, the compounds can be formulated into suitable ointments containing the compounds suspended or dissolved in, for example, mixtures with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax, and water. Alternatively, the compounds can be formulated into suitable lotions or creams containing the active compound suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, 2- octyldodecanol, benzyl alcohol, and water.
Topical application to the lower intestinal tract can be effected in a rectal suppository formulations (see above) or in suitable enema formulations. Dosage levels on the order of about 0.1 mg to about 10,000 mg of the active ingredient compound are useful in the treatment of the above conditions, with preferred levels of about 0.1 mg to about 1,000 mg. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
It is understood, however, that a specific dose level for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the rate of excretion; drug combination; the severity of the particular disease being treated; and the form of administration. As neurotrophic agents, the compounds can be administered with other neurotrophic agents such as neurotrophic growth factor, brain derived growth factor, glial derived growth factor, cilial neurotrophic factor, insulin growth factor and active truncated derivatives thereof, acidic fibroblast growth factor, basic fibroblast growth factor, platelet-derived growth factors, neurotropin-3, and neurotropin 4/5. The dosage level of other neurotrophic drugs will depend upon the factors previously stated and the neurotrophic effectiveness of the drug combination.
The neurotrophic compounds of this invention can be periodically administered to a patient undergoing treatment for neurological disorders or for other reasons in which it is desirable to stimulate neuronal regeneration and growth, such as in various peripheral neuropathic and neurological disorders relating to neurodegeneration. The compounds of this invention can also be administered to mammals other than humans for treatment of various mammalian neurological disorders.
Pharmaceutical Compositions of the Invention
The present invention also relates to a pharmaceutical composition comprising: (i) an effective amount of a compound of the present invention; and (ii) a pharmaceutically acceptable carrier. In a preferred embodiment, such pharmaceutical composition is effective for effecting a neuronal activity, for treating neurodegenerative diseases, neurological disorders, and nerve damage, or for promoting nerve growth in an animal.
The above discussion relating to the utility and administration of the compounds of the present invention also applies to the pharmaceutical compositions of the present invention.
EXAMPLES The following examples are illustrative of the present invention and are not intended to be limitations thereon. Unless otherwise specified, all percentages are based on 100% by weight of the final compound.
EXAMPLE 1
Synthesis of (2S) -2- ( {l-oxo-5-phenyl}-pentyl-l- (3 , 3- dimethyl-1 , 2-dioxopentyl) pyrrolidine ( 1)
(25) -2- (l-oxo-5-phenyl) pentyl-N-benzylpyrrolidine . l-chloro-4-phenylbutane (1.78 g; 10.5 mmol) in 20 mL of THF was added to 0.24 g (10 mmol) of magnesium turnings in 50 mL of refluxing THF. After the addition was complete, the mixture was refluxed for an additional 5 hours, and then added slowly to a refluxing solution of N-benzyl-L-proline ethyl ester (2.30 g (10 mmol) in 100 mL of THF. After 2 hours of further reflux, the mixture was cooled and treated with 5 mL of 2 N HCl. The reaction mixture was diluted with ether (100 mL) and washed with saturated NaHC03, water and brine. The organic phase was dried, concentrated and chromatographed, eluting with 5:1 CH2Cl2:EtOAc to obtain
2.05 g (64%) of the ketone as an oil, lti NMR (CDC13; 300
MHz): 1.49-2.18 (m, 8H) ; 2.32-2.46 (m, 1H) ; 2.56-2.65
(m, 2H) ; 2.97-3.06 (m, 1H) ; 3.17-3.34 (m, 1H) ; 3.44-3.62
(m, 1H) ; 4.02-4.23 (m, 2H) ; 7.01-7.44 (m, 10H) . (2 ) -2- (1-oxo-5-phenyl) pentylpyrrolidine . The ketone compound (500 mg) and palladium hydroxide (20% on carbon, 50 mg) was hydrogenated at 40 psi in a Paar shaker overnight. The catalyst was removed by filtration and the solvent was removed in vacuo. The free amine was obtained as a yellow oil (230 mg; 100%), ■-H NMR (CDC13; 300 MHz): 1.75-2.34 (m, 10H) ; 2.55 (m, 2H) ; 2.95 (dm, 1H) ; 3.45-3.95 (m, 1H) ; 4.05 (m, 1H) ;
7.37 (m, 5H) . (25)-2-(l-oxo-5-phenyl)pentyl-l-(l,2-dioxo-2- methoxyethyl ) pyrrolidine . To a solution of (2S)-2-(l- oxo-4-phenyl) butylpyrrolidine (230 mg; 1.0 mmol) in CH2C12(20 mL) at 0°C was added dropwise methyloxalyl chloride (135 mg; 1.1 mmol). After stirring at 0°C for 3 hours, the reaction was quenched with saturated NH4C1 and the organic phase was washed with water and brine and dried and concentrated. The crude residue was purified on a silica gel column, eluting with 20:1 CH2Cl2:EtOAc to obtain 300 mg of the oxamate as a clear oil (98%), lH NMR (CDC13; 300 MHz): 1.68 (m, 4H) ; 1.91-
2.38 (m, 4H) ; 2.64 (t, 2H) ; 3.66-3.80 (m, 2H) ; 3.77, 3.85 (s, 3H total); 4.16 (m, 2H) ; 4.90 (m, 1H) ; 7.16 (m, 3H) ; 7.27 (m, 2H) .
(25) -2- (f l-oxo-5-phenyl pentyl-1- (3, 3-dimethyl- 1 , 2-dioxopentyl) pyrrolidine (1). To a solution of the oxamate above (250 mg; 0.79 mmol) in anhydrous ether (15 mL) , cooled to - 78°C, was added 1, 1-dimethylpropyl- magnesium chloride (0.8 L of a 1.0 M solution in ether; 0.8 mmol) . After stirring the resulting mixture at - 78°C for 2 hours, the reaction was quenched by the addition of 2 mL of saturated NH4C1, followed by 100 mL of EtOAc. The organic phase was washed with brine, dried, concentrated, and purified on a silica gel column, eluting with 50:1 CH2C12 : EtOAc. Compound 1 was obtained as a clear oil, 120 mg, --H NMR (CDC13, 300 MHz) : δ 0.87 (t, 3H, J=7.5); 1.22 (s, 3H) ; 1.25 (s, 3H) ; 1.67 (m, 4H); 1.70-2.33 (m, 6H) ; 2.61 (t, 2H, J=7.1); 3.52 (m, 2H) ; 4.17 (t, 2H, J=6.2); 4.52 (m, 1H) ; 7.16-7.49 (m, 5H) . Anal. Calcd. for C22H31N03 - H20: C, 70.37; H, 8.86; N, 3.73. Found: 70.48; H, 8.35; N, 3.69. EXAMPLE 2
Synthesis of 2- ( { 1-oxo-6-phenylIhexyl) (2S)-l-(3,3- dimethyl-1 , 2-dioxopentyl) piperidine ( 17 )
The method of Example 1 was utilized to prepare 2- ( { l-oxo-6-phenyl Jhexyl) ( 2S) -1- ( 3 , 3-dimethyl-l , 2- dioxopentyl) piperidine (17), utilizing 2- (ethoxy carboxylate) N-benzylpiperidine and l-chloro-5-phenyl pentane as the starting materials.
EXAMPLE 3 Synthesis of 2- (l-Oxo- -phenyl) butyl-1- (3 , 3-dimethyl-
1 , 2-dioxobutyl) pyrrolidine (63)
The method of Example 1 was utilized to prepare 2-
(l-0xo-4-phenyl) butyl-1- (3, 3-dimethyl-l, 2 - dioxobutyl) pyrrolidine (63), utilizing l-chloro-4- (4- hydroxyphenyl) butane, for l-chloro-4-phenylbutane, as a starting material.
EXAMPLE 4
Synthesis of (2S) -3 , 3-dimethyl-l- \2- (5- (3-pyridyl) pyrrolidinyl]pentane-1 , 2-dione (2 ) Tert-butyl 2-pent-4-enoylpyrrolidinecarboxylate .
To a solution of 3-butenylmagnesiumbromide (97 ml of a
0.5 M solution; 48.4 mmol) in THF (15 ml), cooled to 0°
C and under a nitrogen atmosphere, was added dropwise with stirring a solution of tert-butyl 2- (N-methoxy-N- methylcarbamoyl) pyrrolidine carboxylate (5.0 g, 19.4 mmol) in 15 ml of THF. The mixture was stirred overnight while slowly coming to room temperature. The reaction was quenched by the addition of 80 ml saturated
NH4C1 followed by 50 ml of ethyl acetate and 20 ml of water. The layers were separated, and the aqueous layer was extracted with 2 X 100 ml ethyl acetate. The combined organic layers were dried over MgS04, filtered, concentrated, and the crude product was purified on a silica gel column with 10% ethyl acetate in hexane to obtain the olefin tert-butyl 2-pent-4-enoylpyrrolidine carboxylate as a clear oil, 4.30 g (88%): XH NMR (CDC13, 400 MHz) : d.
Methyl 2-oxo-2- (2-pent-4-enoylpyrrolidinyl) acetate. Trifluoroacetic acid ("TFA"; 65.7 g; 576 mmol) was added dropwise to a solution of 24.3 g (96 mmol) of tert-butyl (2-pent-4-enoyl) pyrrolidinecarboxylate in 45 ml of CH2C12, cooled to 0° C. After stirring for 4 hours, Thin Layer Chromatography ("TLC") indicated that the reaction was complete, and the mixture was concentrated in va cuo to remove TFA. The residue was dissolved in 800 ml of CH2C12 and treated with 2 equivalents of triethylamine while stirring and cooling the mixture in an ice bath. Methyl oxalyl chloride (13.5 g; 106 mmol) was added as a solution in 40 ml CH2C12, in 10 ml portions each followed by 5 ml of Et3N. After the addition, a final 10 ml portion of Et3N was added and the mixture was stirred overnight. It was concentrated, treated with 100 ml of 1:1 ethyl acetate/hexane) , filtered to remove solids, and the concentrated residue purified by SGC, eluting with 1:1 hexane/ethyl acetate, to obtain the oxamate methyl 2-oxo-2- (2-pent-4-enoylpyrrolidinyl) acetate as a brownish oil, 18.80 g (82%). XH NMR (CDC13, 400 MHz): d.
3, 3-Dimethyl-l- (2-pent-4-enoylpyrrolidinyl) pentane- 1, 2-dione . A solution of methyl 2-oxo-2- (2-pent-4- enoylpyrrolidinyl) acetate (21.0 g; 88 mmol) in 150 ml THF was cooled to -78° C, under nitrogen, and treated with 200 ml (180 mmol) of 0.9 M 3, 3-dimethylpropyl magnesium chloride. After stirring for 2.5 hours, TLC indicated that the reaction was complete. It was quenched with 300 ml of saturated NH4C1 followed by 200 ml of ethyl acetate. The layers were separated and the aqueous layer was extracted once more with 300 ml of ethyl acetate. The combined organic layers were dried over MgS04, filtered, concentrated, and the product purified on silica gel with 20% ethyl acetate in hexane, to obtain 3, 3-dimethyl-l- (2-pent-4- enoylpyrrolidinyl) pentane-1, 2-dione as a light yellow oil, 21.0 g (85%) . 3, 3- Dimethyl- 1- \ 2- ( 5- ( 3 -pyridyl ) pent - -enoyl ) pyrrolidinyl] pentane-1 , 2-dione . To a solution of olefin 3, 3-dimethyl-l- (2-pent-4-enoylpyrrolidinyl) pentane-1, 2- dione (500 mg; 1.78 mmol) in 7 ml of Et3N was added 3- bromopyridine (310 mg; 1.96 mmol), palladium (II) acetate (20 mg; 0.09 mmol), and tri- (orthotolyl) phosphine (108 mg; 0.36 mmol), and the mixture was refluxed overnight. The mixture was concentrated and the products purified on a silica gel column, eluting with a gradient from 50% ethyl acetate in hexane to 75% ethyl acetate. Two products were obtained as light yellow oils. The major product (85% of the mixture) was the product of aryl coupling to the terminus of the C-C double bond, 3, 3-dimethyl-l- [2- (5- (3-pyridyl) pent-4- enoyl) pyrrolidinyl] pentane-1, 2-dione; the minor product was the product of coupling at the more substituted carbon. The overall yield of the desired product was 480 mg (75%) .
3, 3-Dimethyl-l- \ 2 - (5- (3-pyridyl) pentanoyl) pyrrolidinyl] pentane-1, 2-dione (2) . Platinum oxide (12 mg) was added to a solution of 3, 3-dimethyl-l- [2- ( 5- (3- pyridyl) pent-4-enoyl) pyrrolidinyl] pentane-1, 2-dione (300 mg; 0.84 mmol) in methanol (8 ml) . The mixture was hydrogenated at 1 atm. for 2.5 hours. TLC indicated that the reaction was complete, and it was filtered through Celite and concentrated. Eluting through a plug of silica gel (ethyl acetate) furnished analytically pure material, 260 mg (87%) . lH NMR (CDC13, 400 MHz) : δ 0.87 (t, 3H,
Figure imgf000043_0001
; 1.21 (s, 6H) ; 1.64 (m, 4H) ; 1.69 (m, 2H) ; 1.78 (m, 1H) ; 1.96 (m, 2H) ; 2.15 (m, 1H) ; 2.53 (m, 1H) ; 2.63 (m, 2H) ; 3.49 (m, 1H) ; 3.53 ( , 1H) ; 4.57 (dd, 1H, J=8.8, 4.8); 7.20 (m, 1H) ; 7.49 (m, 1H,
Figure imgf000044_0001
8.44 (m, 2H) . Anal. Calcd. for C21H30N2O3: C, 70.36; H, 8.44; N, 7.81. Found: C, 70.15; H, 8.54; N, 7.76. TLC: Rj=0.80 (ethyl acetate : ethanol 4:1). Note: this final hydrogenation step may be done using 10% Pd/C, and hydrogenating for 5 hours at 60 psi. Ethanol or ethyl acetate may be used instead of methanol.
EXAMPLE 5 Synthesis of (2S) -3 , 3-dimethyl-l- [2- (5- (4-hydroxy- phenyl)pentanoyl)pyyrolidinyllpentane-1 , 2-dione (68)
The method of Example 4 was utilized to prepare 3, 3-dimethyl-l- (2-pent-4-enoylpyrrolidinyl) pentane-1, 2- dione .
3, 3-Dimethyl-l- (2— f 5— T 4— (phenylmethoxy) phenyl Ipent- 4-enoyl } yrrolidinyl) pentane-1, 2-dione . A solution of 3, 3-dimethyl-l- (2-pent-4-enoylpyrrolidinyl) pentane-1, 2- dione (1.73 g; 6.20 mmol), 4-benzyloxybromobenzene (1.80 g; 6.83 mmol), palladium (II) acetate (70 mg; 0.31 mmol), and tri (orthotolyl) phosphine (380 mg; 1.24 mmol) in triethylamine (23 ml) was refluxed overnight. The mixture was concentrated in vacuo and purified on a silica gel column, eluting with a gradient from 10% ethyl acetate/hexane to 20% ethyl acetate/hexane, to obtain 1.72 g (60%) of 3, 3-dimethyl-l- (2- { 5- [4- (phenylmethoxy) phenyl] pent-4-enoyl }pyrrolidinyl) pentane- 1, 2-dione as a yellow oil. l-{ 2- [5- (4-Hvdroxyphenyl) pentanoyl] pyrrolidinyl )- 3, 3-dimethylpentane-l, 2-dione (68). A mixture of 1.63 g (3.53 mmol) of 3, 3-dimethyl-l- (2- { 5- [4- (phenylmethoxy) phenyl] pent-4-enoyl }pyrrolidinyl) pentane-1, 2-dione and 400 mg of 10% Pd/C in 100 ml of ethyl acetate was hydrogenated at 50 psi overnight. The mixture was filtered through Celite, concentrated, and chromatographed (25% ethyl acetate/hexane) to obtain 800 mg (61%) of l-{2- [5- (4-hydroxyphenyl) pentanoyl] pyrrolidinyl } -3, 3-dimethylpentane-l, 2-dione (68) . lti NMR (CDC13, 400 MHz) : δ 0.87 (t, 3H, J=7.50) ; 1.21 (s, 6H) ; 1.63 (m, 4H) ; 1.67 (m, 2H) ; 1.93 (m, 3H) ; 2.04 (m, 1H) ; 2.52 (m, 4H) ; 3.47 (m, 2H) ; 4.57 (m, 1H) ; 6.72 (d, 2H,
Figure imgf000045_0001
; 7.03 (d, 2H,
Figure imgf000045_0002
. Anal. Calcd. for C22H31N04:
C, 70.75; H, 8.37; N, 3.75. Found: C, 70.64; H, 8.44; N, 3.65. TLC: Rf=0.45 (25% ethyl acetate/hexane) .
EXAMPLE 6 Synthesis of 2-phenyl-1-ethyl 1- (3 , 3-dimethyl-l ,2- dioxopentyl) -2-piperidinecarbothioate (10) Methyl(25)-1-(1, 2 -di oxo- 2 -me t hox ve t h yl ) -2- pyrrolidinecarboxylate . A solution of L-proline methyl ester hydrochloride (3.08 g; 18.60 mmol) in dry methylene chloride was cooled to 0°C and treated with triethylamine (3.92 g; 38.74 mmol; 2.1 eq) . After stirring the formed slurry under a nitrogen atmosphere for 15 min, a solution of methyl oxalyl chloride (3.20 g; 26.12 mmol) in methylene chloride (45 ml) was added dropwise. The resulting mixture was stirred at 0°C for 1.5 hour. After filtering to remove solids, the organic phase was washed with water, dried over MgS04 and concentrated. The crude residue was purified on a silica gel column, eluting with 50% ethyl acetate in hexane, to obtain 3.52 g (88%) of the product as a reddish oil. Mixture of cis-trans amide rotamers; data for trans rotamer given. XH NMR (CDC13) : δ 1.93 (dm, 2H) ; 2.17(m, 2H) ; 3.62(m, 2H) ; 3.71 (s, 3H) ; 3.79, 3.84 (s, 3H total); 4.86 (dd, 1H, J=8.4 , 3.3). Methyl (25) -1- (1.2-dioxo-3, 3-dimethylpentyl ) -2- pyrrolidinecarboxylate . A solution of methyl (25) -1-
( 1 , 2-dioxo-2-methoxyethyl ) -2-pyrrolidinecarboxylate
(2.35 g; 10.90 mmol) in 30 ml of tetrahydrofuran (THF) was cooled to -78°C and treated with 14.2 ml of a 1.0 M solution of 1, 1-dimethylpropylmagnesium chloride in THF. After stirring the resulting homogeneous mixture at - 78°C for three hours, the mixture was poured into saturated ammonium chloride (100 ml) and extracted into ethyl acetate. The organic phase was washed with water, dried, and concentrated, and the crude material obtained upon removal of the solvent was purified on a silica gel column, eluting with 25% ethyl acetate in hexane, to obtain 2.10 g (75%) of the oxamate as a colorless oil, :H NMR (CDC13) : δ 0.88 (t, 3H) ; 1.22, 1.26 (s, 3H each) ; 1.75 (dm, 2H) ; 1.87-2.10 (m, 3H) ; 2.23 (m, 1H) ; 3.54 (m, 2H) ; 3.76 (s, 3H) ; 4.52 (dm, 1H, J=8.4, 3.4).
(25) -1- ( 1 , 2-dioxo-3, 3-dimethylpentyl) -2 - pyrrolidine-carboxylic acid. A mixture of methyl (25)- l- ( l , 2-dioxo- 3 , 3-dimethylpentyl ) -2- pyrrolidinecarboxylate (2.10 g; 8.23 mmol), 1 N LiOH (15 ml) , and methanol (50 ml) was stirred at 0°C for 30 minutes and at room temperature overnight. The mixture was acidified to pH 1 with 1 N HCl, diluted with water, and extracted into 100 ml of methylene chloride. The organic extract was washed with brine and concentrated to deliver 1.73 g (87%) of snow-white solid which did not require further purification, XH NMR (CDC13) : δ 0.87 (t, 3H) ; 1.22, 1.25 (s, 3H each); 1.77 (dm, 2H) ; 2.02 (m, 2H) ; 2.17 (m, 1H) ; 2.25 (m, 1H) ; 3.53 (dd, 2H, J=10.4, 7.3); 4.55 (dd, 1H, J=8.6, 4.1).
2-phenyl-l-ethyl 1- (3, 3-dimethyl-l, 2-dioxopentyl) - 2-piperidinecarbothioate (10). To a solution of (2S)-1- ( 1, 2-dioxo-3, 3-dimethylpentyl) -2-pyrrolidinecarboxylic acid (241 mg; 1.0 mmol) in CH2C12 (10 ml) was added dicyclohexylcarbodiimide (226 mg; 1.1 mmol). After stirring the resulting mixture for 5 minutes, the solution was cooled to 0°C and treated with a solution of phenyl mercaptan (138 mg; 1.0 mmol) and 4- dimethylaminopyridine (6 mg) in 5 ml of CH2C12. The mixture was allowed to warm to room temperature with stirring overnight. The solids were removed by filtration and the filtrate was concentrated in vacuo; the crude residue was purified by flash chromatography (10:1 hexane:EtOAc) to obtain 302 mg (84%) of 10 as an oil, lH NMR (CDC13, 300 MHZ) : δ 0.85 (t, 3H, J=7.5); 1.29
(s, 3H) ; 1.31 (s, 3H) ; 1.70-2.32 (m, 6H) ; 2.92 (t, 2H,
J=7.4); 3.22 (t, 2H, J=7.4); 3.58 (m, 2H) ; 4.72 (m, 1H)
7.23-7.34 (m, 5H) . Anal. Calcd. for C20H27NO3S - 0.4H2O C, 65.15; H, 7.60; N, 3.80. Found: C, 65.41; H, 7.49
N, 3.72.
EXAMPLE 7 Synthesis of 2-phenyl-l-ethyl (2S) -1- (3 , 3-dimethyl- 1 , 2-dioxopentyl) -2-pyrrolidinecarbothioate (9)
Methyl 1- (1, 2-dioxo-2-methoxyethyl) -2-piperidine- carboxylate . A solution of methyl pipecolate hydrochloride (8.50 g; 47.31 mmol) in dry methylene chloride (100 ml) was cooled to 0°C and treated with triethylamine (10.5 g; 103 mmol; 2.1 eq) . After stirring the formed slurry under a nitrogen atmosphere for 15 minutes, a solution of methyl oxalyl chloride (8.50 g; 69.4 mmol) in methylene chloride (75 ml) was added dropwise. The resulting mixture was stirred at 0°C for 1.5 hours. After filtering to remove solids, the organic phase was washed with water, dried over MgS04 and concentrated. The crude residue was purified on a silica gel column, eluting with 50% ethyl acetate in hexane, to obtain 9.34 g (86%) of the product as a reddish oil. Mixture of cis-trans amide rotamers; data for trans rotamer given. -*H NMR (CDC13) : δ 1.22-1.45 (m, 2H) ; 1.67-1.78 (m, 3H) ; 2.29 (m, 1H) ; 3.33 (m, 1H) ; 3.55 (m, 1H) ; 3.76 (s, 3H) ; 3.85, 3.87 (s, 3H total); 4.52 (dd, 1H) . Methyl l-(l,2-dioxo-3, 3-dimethylpentyl ) -2- piperidine-carboxylate . A solution of methyl 1-(1,2- dioxo-2-methoxyethyl) -2-piperidinecarboxylate (3.80 g; 16.57 mmol) in 75 ml of tetrahydrofuran (THF) was cooled to -78°C and treated with 20.7 ml of a 1.0 M solution of 1, 1-dimethyl-propylmagnesium chloride in THF. After stirring the resulting homogeneous mixture at -78°C for three hours, the mixture was poured into saturated ammonium chloride (100 ml) and extracted into ethyl acetate. The organic phase was washed with water, dried, and concentrated, and the crude material obtained upon removal of the solvent was purified on a silica gel column, eluting with 25% ethyl acetate in hexane, to obtain 3.32 g (74%) of the oxamate as a colorless oil, lti NMR (CDC13) : δ 0.88 (t, 3H) ; 1.21, 1.25 (s, 3H each); 1.35-1.80 (m, 7H) ; 2.35 (m, 1H) ; 3.24 (m, 1H) ; 3.41 (m, 1H) ; 3.76 (s, 3H) ; 5.32 (d, 1H) . l-(l,2-dioxo-3, 3-dimethylpentyl ) -2-piperidine- carboxylic acid. A mixture of methyl 1- ( 1, 2-dioxo-3, 3- dimethylpentyl) -2-piperidinecarboxylate (3.30 g; 12.25 mmol), 1 N LiOH (15 ml), and methanol (60 ml) was stirred at 0°C for 30 minutes and at room temperature overnight. The mixture was acidified to pH 1 with 1 N HCl, diluted with water, and extracted into 100 ml of methylene chloride. The organic extract was washed with brine and concentrated to deliver 2.80 g (87%) of snow- white solid which did not require further purification, -*H NMR (CDCI3) : δ 0.89 (t, 3H) ; 1.21, 1.24 (s, 3H each) ; 1.42-1.85 (m, 7H) ; 2.35 (m, 1H) ; 3.22 (d, 1H) ; 3.42(m, 1H) ; 5.31 (d, 1H) .
2-phenyl-l-ethyl (25) -1- (3, 3 -dimethyl- 1 , 2- dioxopentyl) -2-pyrrolidinecarbothioate (9) . To a solution of 1- ( 1 , 2-dioxo-3 , 3-dimethylpentyl ) -2- piperidine-carboxylic acid (255 mg; 1.0 mmol) in CH2C12 (10 ml) was added dicyclohexylcarbodiimide (226 mg; 1.1 mmol) . After stirring the resulting mixture for 5 minutes, the solution was cooled to 0°C and treated with a solution of phenyl mercaptan (138 mg; 1.0 mmol) and 4- dimethylaminopyridine (6 mg) in 5 ml of CH2C12. The mixture was allowed to warm to room temperature with stirring overnight. The solids were removed by filtration and the filtrate was concentrated in vacuo; the crude residue was purified by flash chromatography (10:1 hexane:EtOAc) to obtain 300 mg (80%) of 9 as an oil, --H NMR (CDC13, 300 MHZ): d 0.94 (t, 3H, J=7.5); 1.27
(s, 3H) ; 1.30 (s, 3H) ; 1.34-1.88 (m, 7H) ; 2.45 (m, 1H) ;
2.90 (t, 2H, J=7.7); 3.26 (t, 2H, J=7.7 ) ; 3.27 ( , 1H) ;
3.38 (m, 1H) ; 5.34 (m, 1H) ; 7.24-7.36 ( , 5H) . Anal.
Calcd. for C21H29N03S: C, 67.17; H, 7.78; N, 3.73. Found: C, 67.02; H, 7.83; N, 3.78.
EXAMPLE 8
A patient is suffering from a condition or disorder requiring stimulation of damaged neurons, promotion of neuronal regeneration, prevention of neurodegeneration, or treatment of a neurological disorder; wherein the neurological disorder is selected from the group consisting of peripheral neuropathy caused by physical injury or disease state, traumatic injury to the brain, physical damage to the spinal cord, stroke associated with brain damage, and neurological disorders relating to neurodegeneration; and wherein the neurological disorder relating to neurodegeneration is selected from the group consisting of AlzheimerY Disease, HuntingtonY Disease, ParkinsonY Disease, and amyotrophic lateral sclerosis. (25) -3, 3-dimethyl-l- [2- (5- (3-pyridyl) pyrrolidinyl] pentane-1, 2-dione, 2- (1-Oxo- 4-phenyl ) -butyl-1- ( 3 , 3-dimethyl-l , 2 - dioxobutyl) pyrrolidine, (2S)-3, 3-dimethyl-l- [2- (5- (4- hydroxyphenyl) pentanoyl) pyrrolidinyl] pentane-1, 2-dione, or 2- ( { l-oxo-6-phenyl }-hexyl) (2S) -1- (3, 3-dimethyl-l, 2- dioxopentyl) piperidine, or a pharmaceutical composition comprising the same, may be administered to the patient. Protection from or recovery from the effects of the described condition (s) or disorder (s) is expected to occur following treatment.
The compounds of the present invention have an affinity for the FK506 binding protein, particularly FKBP12. The inhibition of the prolyl peptidyl cis-trans isomerase activity of FKBP may be measured as an indicator of this affinity and as a possible indicator of neurotrophic activity.
i^ Test Procedure
Inhibition of the peptidyl-prolyl isomerase (rotamase) activity of the inventive compounds can be evaluated by known methods described in the literature (Harding et al., Na ture, 1989, 341:758-760; Holt et al . J. Am . Chem . Soc , 115:9923-9938). These values are obtained as apparent KX'S, and are presented for representative compounds in Table IV. The cis-trans isomerization of an alanine-proline bond in a model substrate, N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide, is monitored spectrophotometrically in a chymotrypsin- coupled assay, which releases para-nitroanilide from the trans form of the substrate. The inhibition of this reaction caused by the addition of different concentrations of inhibitor is determined, and the data is analyzed as a change in first-order rate constant as a function of inhibitor concentration to yield the apparent K values.
In a plastic cuvette are added 950 ml of ice cold assay buffer (25 mM HEPES, pH 7.8, 100 mM NaCl), 10 ml of FKBP (2.5 mM in 10 mM Tris-Cl pH 7.5, 100 mM NaCl, 1 mM dithiothreitol), 25 ml of chymotrypsin (50 mg/ml in 1 mM HCl) and 10 ml of test compound at various concentrations in dimethyl sulfoxide. The reaction is initiated by the addition of 5 ml of substrate (succinyl-Ala-Phe-Pro-Phe-para-nitroanilide, 5 mg/ml in 2.35 mM LiCl in trifluoroethanol) .
The absorbance at 390 nm versus time is monitored for 90 seconds using a spectrophotometer and the rate constants are determined from the absorbance versus time data files.
The data for these experiments for representative compounds are presented in Table IV under the column "Ki". The neurotrophic effects of the compounds of the present invention can be demonstrated in cellular biological experiments in vi tro, as described below.
Chick Dorsal Root Ganglion Cultures and Neurite Outgrowth
The neurotrophic effects of the FKBP inhibitor compounds were demonstrated by evaluating the ability of the compounds to promote neurite outgrowth in cultured chick sensory neurons from dorsal root ganglia. Dorsal root ganglia were dissected from chick embryos of ten day gestation. Whole ganglion explants were cultured on thin layer Matrigel-coated 12 well plates with Liebovitz L15 plus high glucose media supplemented with 2 mM glutamine and 10% fetal calf serum, and also containing 10 μM cytosine β-D arabinofuranoside (Ara C) at 37°C in an environment containing 5% C02. Twenty-four hours later, the DRGs were treated with various concentrations of nerve growth factor, immunophilin ligands or combinations of NFG plus drugs. Forty-eight hours after drug treatment, the ganglia were visualized under phase contrast or Hoffman Modulation contrast with a Zeiss Axiovert inverted microscope. Photomicrographs of the explants were made, and neurite outgrowth was quantitated. Neurites longer than the DRG diameter were counted as positive, with total number of neurites quantitated per each experimental condition. Three to four DRGs are cultured per well, and each treatment was performed in duplicate.
Dose-response curves were generated from which ED50 values were obtained. The results of these experiments are presented in Table IV under the column "ED50". Representative photomicrographs of untreated (control) sensory neurons and of sensory neurons treated with compound 1 (10 pM, 1 nM, 1 μM) , and related compounds 2- Phenyl-1-ethyl (2S) -1- (3, 3-dimethyl-l, 2-dioxopentyl) -2- pyrrolidinecarbothioate (10 pM, 1 nM, 100 nM) and 2- Phenyl-1-ethyl 1- (3, 3-dimethyl-l, 2-dioxopentyl) -2- piperidinecarbothioate (10 pM, 1 nM, 100 nM) promoting neurite outgrowth in sensory neurons are shown in FIG. 's l(A-D), 2(A-D), and 3 (A-D) , respectively.
MPTP Model of Parkinson's Disease
The remarkable neurotrophic and neuroregenerative effects of the present inventive compounds were further demonstrated in an animal model of neurodegenerative disease. MPTP lesioning of dopaminergic neurons in mice was used as an animal model of Parkinson's Disease. Four week old male CDl white mice were dosed i.p. with 30 mg/kg of MPTP for 5 days. Test compounds (4 mg/kg), or vehicle, were administered s.c. along with the MPTP for 5 days, as well as for an additional 5 days following cessation of MPTP treatment. At 18 days following MPTP treatment, the animals were sacrificed and the striata were dissected and homogenized. Immunostaining was performed on saggital and coronal brain sections using anti-tyrosine hydroxylase 1 g to quantitate survival and recovery of dopaminergic neurons. In animals treated with MPTP and vehicle, a substantial loss of functional dopaminergic terminals was observed as compared to non-lesioned animals. Lesioned animals receiving test compounds showed a significant recovery of TH-stained dopaminergic neurons. The results of these experiments are presented in TABLE IV under the column "% TH recovery". Quantitation for the recovery of TH-positive dopaminergic neurons in the striatum of animals receiving compounds of the invention, including compound 1, and for representative control and lesioned animals not receiving the test drugs, are presented in FIG. 4.
TABLE IV
In Vitro Test Results
Compound Ki. nM ED50. nM % TH recovery
1 31 0.4 23
2 210 — —
3 85 — —
9 104 0.5 61
10 12 0.8 54
11 299 0.36 53
12 442 0.025 —
14 313 0.9 48
28 362 — 52
29 1698 — —
30 34 0.9 48
31 62 — —
32 7 — 56
33 68 — —
34 8.9 0.011 37.32 35 347
36 1226
37 366
38 28 39 259
40 188 - 25
41 31
42 757
43 21 - 50 44 127 -- 28
45 1334
46 55 - 62
47 33
48 6 49 261
50 37
51 30
52 880
53 57 54 79
55 962
56 90
57 139
58 196 59 82
60 163
61 68
62 306 5 38
63 177 64 284
65 49 - 23 66 457 - 25
67 788
All publications and patents identified above are hereby incorporated by reference.
The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the invention and all such modifications are intended to be included within the scope of the following claims.

Claims

WE CLAIM :
1. A neurotrophic, low molecular weight, small molecule heterocyclic ketone or thioester compound.
2. The compound of claim 1, wherein the compound is non-immunosuppressive .
3. The compound of claim 1, wherein the compound has an affinity for an FKBP-type immunophilin .
4. A pharmaceutical composition comprising: (i) an effective amount of the compound of claim 1; and (ii) a pharmaceutically acceptable carrier.
5. A method of effecting a neuronal activity in an animal, comprising administering to said animal an effective amount of the compound of claim 1.
6. The method of claim 5, wherein the neuronal activity is selected from the group consisting of stimulation of damaged neurons, promotion of neuronal regeneration, prevention of neurodegeneration, and treatment of a neurological disorder.
7. The method of claim 6, wherein the neurological disorder is selected from the group consisting of peripheral neuropathy caused by physical injury or disease state, traumatic injury to the brain, physical damage to the spinal cord, stroke associated with brain damage, and neurological disorders relating to neurodegeneration .
8. The method of claim 7, wherein the neurological disorder relating to neurodegeneration is selected from the group consisting of Alzheimer's Disease, Huntington' s Disease, Parkinson's Disease, and amyotrophic lateral sclerosis.
A compound of formula II;
Figure imgf000057_0001
or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein n is 1 or 2,
X is 0 or S,
Z is selected from the group consisting of CH2, CHRX and CR^;
Rl r R2, and R3 are independently selected from the group consisting of C^Cs straight or branched chain alkyl, C2-C5 straight or branched chain alkenyl, and Ar, wherein said Rl r R2, or R3 is unsubstituted or substituted with one or more substituents independently selected from the group consisting of halo, trifluoromethyl, nitro,
Figure imgf000057_0002
straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, hydroxy, C^C^ alkoxy, C2-C4 alkenyloxy, phenoxy, benzyloxy, amino, and Ar;
R4 is selected from the group consisting of C^Cg straight or branched chain alkyl, C2-C9 straight or branched chain alkenyl, C3-C8 cycloalkyl, C5-C7 cycloalkenyl, and Ar; and
Ar is aryl, wherein said Ar is unsubstituted or substituted with halo, trifluoromethyl, hydroxy, nitro, Cj^-Cg straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1-C4 alkoxy, C2-C4 alkenyloxy, phenoxy, benzyloxy, or amino.
10. The compound of claim 9, wherein: n is 1; and X is 0.
11. The compound of claim 10, wherein Z is CH2.
12. The compound of claim 11, wherein R3 is 3- pyridylpropyl and R4 is 1, 1-dimethylpropyl .
13. The compound of claim 11, wherein R3 is 2- phenylethyl, and R4 is tert-butyl.
14. The compound of claim 11, wherein R3 is 3- (4- hydroxyphenyl) propyl and R4 is 1, 1-dimethylpropyl .
15. The compound of claim 11, which is selected from the group consisting of:
(25) -3, 3-dimethyl-l- [2- (5-phenylpentanoyl) pyrrolidinyl] pentane-1, 2-dione;
( 2 S) -3, 3-dimethyl-l- [2- (5- (3-pyridyl) pyrrolidinyl] pentane-1, 2-dione;
(2S) -2- ( { l-oxo-5-phenyl}pentyl-l- (3, 3-dimethyl-l, 2- dioxobutyl) pyrrolidine;
(2S) -3, 3-dimethyl-l- [2- (5- (4-hydroxyphenyl) pentanoyl) pyrrolidinyl] pentane-1, 2-dione; (2S) -2- ( { l-0xo-5-phenyl }pentyl-l- (2-Cyclohexyl-l, 2- dioxoethyl) pyrrolidine;
2- (1-Oxo- -phenyl) -butyl-1- (3, 3-dimethyl-l, 2- dioxobutyl) pyrrolidine;
(2S)-2-[5,5-di ( 4 -Fluorophenyl ) pentanoyl] -1- (3, 3 dimethyl-1, 2-pentanedione) pyrrolidine; and pharmaceutically acceptable salts, esters, or solvates thereof.
16. The compound of claim 15 which is (2S)-3,3- dimethyl- 1- [2- (5- (3-pyridyl) pyrrolidinyl] pentane-1, 2- dione, or a pharmaceutically acceptable salt, ester, or solvate thereof.
17. The compound of claim 15 which is 2-(l-Oxo-4- p h e n y l ) - b u t y l - 1 - ( 3 , 3 - d i me t h y l - l , 2 - dioxobutyl) pyrrolidine, or a pharmaceutically acceptable salt, ester, or solvate thereof.
18. The compound of claim 15 which is (2S)-3,3- dimethyl-1- [2- (5- (4-hydroxyphenyl) pentanoyl) pyrrolidinyl] pentane-1, 2-dione, or a pharmaceutically acceptable salt, ester, or solvate thereof.
19. The compound of claim 9, wherein: n is 1; and
X is S.
20. The compound of claim 19, wherein Z is CH2.
21. The compound of claim 9, wherein: n is 2; and X is 0.
22. The compound of claim 21, wherein Z is CH2.
23. The compound of claim 22, wherein R3 is 4- phenylbutyl and R4 is 1, 1-dimethylpropyl .
24. The compound of claim 22, which is selected from the group consisting of: 2- ( { 1-Oxo- 6-phenyY-hexyl-l- ( 2 -Cyclohexyl -1 , 2- dioxoethyl) piperidine;
2- ({ 1-oxo-6-phenyl}-hexyl) (2S) -1- (3, 3-dimethyl- 1 , 2-dioxopentyl) piperidine; 3, 3-Dimethyl-1- [2- (5-phenylpentanoyl)piperidino] - 1, 2-pentanedione; and pharmaceutically acceptable salts, esters, or solvates thereof.
25. The compound of claim 24 which is 2-({l-oxo-6- phenyl}-hexyl) (25) -1- (3, 3-dimethyl-l, 2 - dioxopentyl ) piperidine or a pharmaceutically acceptable salt, ester, or solvate thereof.
26. The compound of claim 9, wherein: n is 2; and X is S.
27. The compound of claim 26, wherein Z is CH2.
28. The compound of claim 26, wherein Z is CHRX ,
29. The compound of claim 28, which is 2-({l-Oxo- [2-{2 ' -phenyl} ethyl] -4-phenyl } -butyl-1- (3, 3-dimethyl- 1, 2-dioxobutyl) piperidine .
30. A pharmaceutical composition comprising:
(i) an effective amount of the compound of claim 9 ; and (ii) a pharmaceutically acceptable carrier.
31. The pharmaceutical composition of claim 30, wherein, in said compound: n is 1; and X is 0.
32. The pharmaceutical composition of claim 31, wherein, in said compound, Z is CH2.
33. The pharmaceutical composition of claim 32, wherein R3 is 3-pyridylpropyl and R4 is 1,1- dimethylpropyl .
34. The pharmaceutical composition of claim 32, wherein R3 is 2-phenylethyl, and R4 is tert-butyl.
35. The pharmaceutical composition of claim 32, wherein R3 is 3- (4-hydroxyphenyl) propyl and R4 is 1,1- dimethylpropyl .
36. The pharmaceutical composition of claim 32, wherein said compound is selected from the group consisting of:
(2S) -3, 3-dimethyl-l- [2- (5-phenylpentanoyl) pyrrolidinyl] pentane-1, 2-dione; (2S) -3, 3-dimethyl-l- [2- (5- (3-pyridyl) pyrrolidinyl] pentane-1, 2-dione;
(2S) -2- ( { l-oxo-5-phenyl}pentyl-l- (3, 3-dimethyl-l, 2- dioxobutyl) pyrrolidine;
(2S) -3, 3-dimethyl-l- [2- (5- (4-hydroxyphenyl) pentanoyl) pyrrolidinyl] pentane-1, 2-dione;
(25) -2- ( { l-0xo-5-phenyl}pentyl-l- (2-Cyclohexyl-l, 2- dioxoethyl) pyrrolidine;
2- (1-Oxo- 4 -phenyl) -butyl-1- (3, 3-dimethyl-l, 2- dioxobutyl) pyrrolidine; (25) -2- [5, 5-di ( 4 -Fluorophenyl ) pentanoyl] -1- (3, 3 dimethyl-1, 2-pentanedione) pyrrolidine; and pharmaceutically acceptable salts, esters, or solvates thereof.
37. The pharmaceutical composition of claim 36 wherein said compound is (2S) -3, 3-dimethyl-l- [2- (5- ( 3- pyridyl ) pyrrolidinyl ] pentane-1 , 2-dione , or a pharmaceutically acceptable salt, ester, or solvate thereof.
38. The pharmaceutical composition of claim 36 wherein said compound is 2- ( l-Oxo-4-phenyl) -butyl-1-
( 3 , 3-dimethyl-l , 2-dioxobutyl ) pyrrolidine, or a pharmaceutically acceptable salt, ester, or solvate thereof.
39. The pharmaceutical composition of claim 36 wherein said compound is (2S) -3, 3-dimethyl-l- [2- (5- ( 4- hydroxyphenyl) pentanoyl) pyrrolidinyl] pentane-1, 2-dione, or a pharmaceutically acceptable salt, ester, or solvate thereof .
40. The pharmaceutical composition of claim 30, wherein, in said compound: n is 1; and X is S.
41. The pharmaceutical composition of claim 40, wherein, in said compound, Z is CH2.
42. The pharmaceutical composition of claim 30, wherein, in said compound: n is 2; and X is 0.
43. The pharmaceutical composition of claim 42, wherein, in said compound, Z is CH2.
44. The pharmaceutical composition of claim 43, wherein R3 is 4-phenylbutyl and R4 is 1, 1-dimethylpropyl .
45. The pharmaceutical composition of claim 43, wherein said compound is selected from the group consisting of:
2- ( { l-Oxo-6-phenyl}-hexyl-l- ( 2 -Cyclohexyl- 1 , 2- dioxoethyl) piperidine;
2- ({l-oxo-6-phenyl}-hexyl) (2S)-1- ( 3, 3-dimethyl- 1, 2-dioxopentyl) piperidine;
3, 3-Dimethyl-l- [2- (5-phenylpentanoyl ) piperidino] - 1, 2-pentanedione; and pharmaceutically acceptable salts, esters, or solvates thereof .
46. The pharmaceutical composition of claim 45 wherein said compound is 2- ( { l-oxo-6-phenyl } -hexyl) (25)-l-(3, 3-dimethyl-l, 2-dioxopentyl) piperidine.
47. The pharmaceutical composition of claim 30, wherein, in said compound: n is 2; and X is S.
48. The pharmaceutical composition of claim 47, wherein, in said compound, Z is CH2.
49. The pharmaceutical composition of claim 47, wherein, in said compound, Z is CHRi .
50. The pharmaceutical composition of claim 49, wherein said compound is 2- ({ 1-Oxo- [2- { 2 ' -phenyl } ethyl] - 4-phenyl}-butyl-l- (3, 3-dimethyl-l, 2-dioxobutyl) piperidine .
51. A method for effecting a neuronal activity in an animal, comprising administering to the animal an effective amount of the compound of claim 9.
52. The method of claim 51, wherein the neuronal activity is selected from the group consisting of stimulation of damaged neurons, promotion of neuronal regeneration, prevention of neurodegeneration and treatment of neurological disorder.
53. The method of claim 52, wherein the neurological disorder is selected from the group consisting of peripheral neuropathy caused by physical injury or disease state, traumatic injury to the brain, physical damage to the spinal cord, stroke associated with brain damage, and neurological disorder relating to neurodegeneration .
54. The method of claim 53, wherein the neurological disorder relating to neurodegeneration is selected from the group consisting of Alzheimer's Disease, Huntington' s Disease, Parkinson's Disease, and amyotrophic lateral sclerosis.
55. The method of claim 51, wherein, in said compound: n is 1; and X is 0.
56. The method of claim 55, wherein, in said compound, Z is CH2.
57. The method of claim 56, wherein R3 is 3- pyridylpropyl and R4 is 1, 1-dimethylpropyl .
58. The method of claim 56, wherein R3 is 2- phenylethyl, and R4 is tert-butyl.
59. The method of claim 56, wherein R3 is 3- (4- hydroxyphenyl) propyl and R4 is 1, 1-dimethylpropyl .
60. The method of claim 56, wherein said compound is selected from the group consisting of: (2S)-3,3-dimethyl-l-[2-(5-phenylpentanoyl) pyrrolidinyl] pentane-1, 2-dione;
(2S) -3, 3-dimethyl-l- [2- (5- (3-pyridyl) pyrrolidinyl] pentane-1, 2-dione;
(25) -2- ( { l-oxo-5-phenyl}pentyl-l- (3, 3-dimethyl-l, 2- dioxobutyl) pyrrolidine;
(25) -3, 3-dimethyl-l- [2- (5- (4-hydroxyphenyl) pentanoyl) pyrrolidinyl] pentane-1, 2-dione;
(2S) -2- ( { l-Oxo-5-phenyl }pentyl-l- (2-Cyclohexyl-l, 2- dioxoethyl) pyrrolidine; 2-(l-Oxo-4-phenyl)-butyl-l-(3, 3-dimethyl-l, 2- dioxobutyl) pyrrolidine;
(2S) -2- [5, 5-di (4 -Fluorophenyl) pentanoyl] -1- (3, 3 dimethyl-1, 2-pentanedione) pyrrolidine; and pharmaceutically acceptable salts, esters, or solvates thereof.
61. The method of claim 61 wherein said compound is (2S) -3, 3-dimethyl-l- [2- (5- (3-pyridyl) pyrrolidinyl] pentane-1, 2-dione, or a pharmaceutically acceptable salt, ester, or solvate thereof.
62. The method of claim 61 wherein said compound is 2- (1-Oxo- 4 -phenyl) -butyl-1- (3, 3-dimethyl-l, 2- dioxobutyl) pyrrolidine, or a pharmaceutically acceptable salt, ester, or solvate thereof.
63. The method of claim 61, wherein said compound is (25) -3, 3-dimethyl-l- [2- (5- (4-hydroxyphenyl) pentanoyl) pyrrolidinyl] pentane-1 , 2-dione, or a pharmaceutically acceptable salt, ester, or solvate thereof.
64. The method of claim 51, wherein, in said compound: n is 1; and X is S.
65. The method of claim 64, wherein, in said compound, Z is CH2.
66. The method of claim 51, wherein, in said compound: n is 2; and X is 0.
67. The method of claim 66, wherein, in said compound, Z is CH2.
68. The method of claim 67, wherein R3 is 4- phenylbutyl and R4 is 1, 1-dimethylpropyl .
69. The method of claim 67, wherein said compound is selected from the group consisting of:
2- ( { l-Oxo-6-phenyl}-hexyl-l- ( 2 -Cyclohexyl- 1 , 2- dioxoethyl) piperidine;
2- ( {l-oxo-6-phenyl}-hexyl) (25) -1- (3, 3-dimethyl- 1, 2-dioxopentyl) piperidine;
3, 3-Dimethyl-1- [2- ( 5-phenylpentanoyl ) piperidino] - 1, 2-pentanedione; and pharmaceutically acceptable salts, esters, or solvates thereof.
70. The method of claim 69, wherein said compound is 2-({l-oxo-6-phenyl}-hexyl) (2S) -1- (3, 3-dimethyl-l, 2- dioxopentyl) piperidine .
71. The method of claim 51, wherein, in said compound: n is 2; and X is S.
72. The method of claim 71, wherein, in said compound, Z is CH2.
73. The method of claim 71, wherein in said compound, Z is CHRj_ .
74. The method of claim 73, wherein said compound is 2- ( { 1-Oxo- [2- { 2 ' -phenyl } ethyl] - -phenyl } -butyl-1- (3, 3-dimethyl-l, 2-dioxobutyl) piperidine.
75. The compound of claim 1, wherein the compound has a molecular weight no more than about 800 daltons.
76. The compound of claim 1, wherein the compound has a molecular weight no more than about 500 daltons.
77. The compound of claim 1, wherein the compound has a molecular weight no more than about 330 daltons.
78. The compound of claim 1, wherein the compound exhibits a Chick Dorsal Root Ganglion Neurite Outgrowth
Assay ED50 value of less than about 10 nM.
79. The compound of claim 1, wherein the compound exhibits a Chick Dorsal Root Ganglion Neurite Outgrowth Assay ED50 value of less than about 1.0 nM.
80. The compound of claim 1, wherein the compound exhibits a Chick Dorsal Root Ganglion Neurite Outgrowth Assay ED50 value of less than about 0.1 nM.
81. The compound of claim 1, wherein the compound exhibits an MPTP Assay value which is greater than about 20% recovery of TH-stained dopaminergic neurons.
82. The compound of claim 1, wherein the compound exhibits an MPTP Assay value which is greater than about 35% recovery of TH-stained dopaminergic neurons.
83. The compound of claim 1, wherein the compound exhibits an MPTP Assay value which is greater than about 50% recovery of TH-stained dopaminergic neurons.
PCT/US2000/023742 1999-11-22 2000-08-30 Heterocyclic ketone and thioester compounds and uses WO2001038304A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002391575A CA2391575A1 (en) 1999-11-22 2000-08-30 Heterocyclic ketone and thioester compounds and uses
MXPA02005206A MXPA02005206A (en) 1999-11-22 2000-08-30 Heterocyclic ketone and thioester compounds and uses.
EP00959575A EP1233945A1 (en) 1999-11-22 2000-08-30 Heterocyclic ketone and thioester compounds and uses
AU70869/00A AU784388B2 (en) 1999-11-22 2000-08-30 Heterocyclic ketone and thioester compounds and uses
JP2001539860A JP2003514893A (en) 1999-11-22 2000-08-30 Heterocyclic ketone and thioester compounds and their use
HK02108037.6A HK1046530A1 (en) 1999-11-22 2002-11-05 Heterocyclic ketone and thioester compounds and uses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/444,200 US6218424B1 (en) 1996-09-25 1999-11-22 Heterocyclic ketone and thioester compounds and uses
US09/444,200 1999-11-22

Publications (1)

Publication Number Publication Date
WO2001038304A1 true WO2001038304A1 (en) 2001-05-31

Family

ID=23763911

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/023742 WO2001038304A1 (en) 1999-11-22 2000-08-30 Heterocyclic ketone and thioester compounds and uses

Country Status (8)

Country Link
US (5) US6218424B1 (en)
EP (1) EP1233945A1 (en)
JP (1) JP2003514893A (en)
AU (1) AU784388B2 (en)
CA (1) CA2391575A1 (en)
HK (1) HK1046530A1 (en)
MX (1) MXPA02005206A (en)
WO (1) WO2001038304A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096420A2 (en) * 2001-05-29 2002-12-05 Guilford Pharmaceuticals Inc. Method for treating nerve injury caused by surgery
WO2003048150A1 (en) * 2001-12-06 2003-06-12 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. Substituted 5-membered n-heterocyclic compounds and their uses for treating or preventing neurodegenerative diseases
US8481711B2 (en) 2010-07-06 2013-07-09 Hidenori Kamanishi Neurite outgrowth agent

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218424B1 (en) * 1996-09-25 2001-04-17 Gpi Nil Holdings, Inc. Heterocyclic ketone and thioester compounds and uses
US5846979A (en) * 1997-02-28 1998-12-08 Gpi Nil Holdings, Inc. N-oxides of heterocyclic esters, amides, thioesters, and ketones
DE10150203A1 (en) * 2001-10-12 2003-04-17 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitor in treatment of cancer
CA2541014A1 (en) * 2003-10-01 2005-04-14 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
ATE440340T1 (en) 2005-03-14 2009-09-15 Gtech Corp SYSTEM AND METHOD FOR PROCESSING MARKINGS IN A FORM
US8059168B2 (en) * 2005-03-14 2011-11-15 Gtech Corporation System and method for scene change triggering
US7598261B2 (en) * 2005-03-31 2009-10-06 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
US7576207B2 (en) 2006-04-06 2009-08-18 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
AU2007294968A1 (en) * 2006-09-12 2008-03-20 Adolor Corporation Use of N-containing spirocompounds for the enhancement of cognitive function
US10780034B2 (en) 2016-11-03 2020-09-22 Repairogen Corp. Cosmetic compositions containing quinones and their topical use on skin and hair
US11013673B2 (en) 2016-11-03 2021-05-25 Repairogen Corp. Cosmetic compositions containing quinones and their topical use on skin and hair
IT201900025066A1 (en) * 2019-12-20 2021-06-20 Univ Degli Studi Di Firenze COMPOSED OF FORMULA (I) AND SENSOR UNIT THAT INCLUDES IT

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040633A1 (en) * 1995-06-07 1996-12-19 Guilford Pharmaceuticals Inc. Small molecule inhibitors of rotamase enzyme activity
WO1998013343A1 (en) * 1996-09-25 1998-04-02 Guilford Pharmaceuticals Inc. Heterocyclic thioesters and ketones
WO1998013355A1 (en) * 1996-09-25 1998-04-02 Guilford Pharmaceuticals Inc. Heterocyclic esters and amides
WO1998037885A1 (en) * 1997-02-28 1998-09-03 Guilford Pharmaceuticals Inc. N-oxides of heterocyclic esters, amides, thioesters, and ketones
WO1998037882A1 (en) * 1997-02-27 1998-09-03 Guilford Pharmaceuticals Inc. Method of using neurotrophic carbamates and ureas

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3203961A (en) 1963-03-21 1965-08-31 Indolylethylpyrromdone compounds
US3458515A (en) 1966-07-21 1969-07-29 American Home Prod Piperazine substituted pyrroles
US3459770A (en) 1966-12-07 1969-08-05 American Home Prod Indoleglyoxyloylpyrroles
US4053599A (en) 1976-02-26 1977-10-11 American Hoechst Corporation Piperazionalkylpyrrolobenzoxazalkanes
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4390695A (en) 1980-06-23 1983-06-28 E. R. Squibb & Sons, Inc. Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids
US4310461A (en) 1980-06-23 1982-01-12 E. R. Squibb & Sons, Inc. Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids
US4578474A (en) 1980-06-23 1986-03-25 E. R. Squibb & Sons, Inc. Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids
US4950649A (en) 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
GR75019B (en) 1980-09-17 1984-07-12 Univ Miami
DE19575012I2 (en) 1980-10-23 2002-01-24 Schering Corp Carboxyalkyl dipeptides Process for their preparation and medicaments containing them
ZA817261B (en) 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
ZA826022B (en) 1981-08-21 1983-08-31 Univ Miami Novel complex amido and imido derivatives of carboxyalkyl peptides and thioethers and ethers of peptides
US4766110A (en) 1981-08-21 1988-08-23 Ryan James W Novel complex amido and imido derivatives of carboxyalkyl peptides
DE3360065D1 (en) 1982-03-08 1985-03-28 Schering Corp Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them
US4531964A (en) 1982-09-13 1985-07-30 Nippon Kayaku Kabushiki Kaisha Heterocyclic compound and a herbicidal composition containing said compound
US4574079A (en) 1983-05-27 1986-03-04 Gavras Haralambos P Radiolabeled angiotensin converting enzyme inhibitors for radiolabeling mammalian organ sites
IT8483334A0 (en) 1984-03-13 1984-03-13 Umberto De Faveri BASKET PERFECTED FOR THE GAME OF BASKETBALL OR BASKETBALL.
US4593102A (en) 1984-04-10 1986-06-03 A. H. Robins Company, Inc. N-[(amino)alkyl]-1-pyrrolidine, 1-piperidine and 1-homopiperidinecarboxamides (and thiocarboxamides) with sulfur linked substitution in the 2, 3 or 4-position
DE3508251A1 (en) 1985-03-08 1986-09-11 Merck Patent Gmbh, 6100 Darmstadt Dipeptides
CN86101850A (en) 1985-03-22 1987-02-04 森得克斯(美国)有限公司 N, the manufacture method and the purposes of N '-dialkyl group guanidine radicals dipeptides
DE3774975D1 (en) 1986-09-10 1992-01-16 Syntex Inc SELECTIVE AMIDINATION OF DIAMINES.
DE3712364A1 (en) 1987-04-11 1988-10-27 Hoechst Ag NEW PYRROLIDIN-2 (1,3-DICARBONYL) DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THE CONTAINERS AND THE USE THEREOF
IT1206078B (en) 1987-06-03 1989-04-14 Polifarma Spa PROCEDURE FOR THE PRODUCTION OF 3-INDOLPIRUVIC ACID AND ITS DERIVATIVES THEIR PHARMACEUTICAL USE
US4857524A (en) * 1987-08-08 1989-08-15 Kissei Pharmaceutical Co., Ltd. Thiazolidine compounds and therapeutic method
JPH01250370A (en) * 1987-12-23 1989-10-05 Zeria Pharmaceut Co Ltd Novel amino acid imide derivative, its production and use thereof
US5187156A (en) 1988-03-16 1993-02-16 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same
US5232923A (en) 1988-03-18 1993-08-03 Mitsui Toatsu Chemicals, Incorporated Catechol derivatives and pharmaceutical preparations containing same
IL90872A0 (en) 1988-07-08 1990-02-09 Smithkline Beckman Corp Retroviral protease binding peptides
DE3931051A1 (en) 1988-09-22 1990-03-29 Hoechst Ag New herbicidal amine salts of herbicidal acids
US5166317A (en) 1988-10-31 1992-11-24 Houston Biotechnology Incorporated Neurotrophic factor
CA2004028C (en) * 1988-12-08 1998-09-22 Motoki Torizuka Condensed benzene derivative
EP0378318A1 (en) 1989-01-11 1990-07-18 Merck & Co. Inc. Process for synthesis of FK-506 and tricarbonyl intermediates
WO1990012805A1 (en) 1989-04-15 1990-11-01 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Postostatin and related compound thereof, or their salts
US5359138A (en) 1989-04-15 1994-10-25 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Poststatin and related compounds or salts thereof
US5164525A (en) 1989-06-30 1992-11-17 Merck & Co., Inc. Synthetic process for fk-506 type macrolide intermediates
US5215969A (en) 1989-08-11 1993-06-01 Hahnemann University Dopaminergic neurotrophic factor for treatment of Parkinson's disease
NZ234883A (en) 1989-08-22 1995-01-27 Merck Frosst Canada Inc Quinolin-2-ylmethoxy indole derivatives, preparation and pharmaceutical compositions thereof
GB8922026D0 (en) 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US5115098A (en) 1990-02-28 1992-05-19 President And Fellows Of Harvard College End-blocked peptides inhibiting binding capacity of gp120
JPH04211648A (en) 1990-07-27 1992-08-03 Nippon Kayaku Co Ltd Keto-acid amide derivative
DE4015255A1 (en) 1990-05-12 1991-11-14 Hoechst Ag OXALYL-AMINOSA-E-LEED DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICAMENT FOR INHIBITING THE PROLYL HYDROXYLASE
US5192773A (en) 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
WO1992003472A1 (en) 1990-08-24 1992-03-05 The Upjohn Company Peptides containing amino-polyols as transition-state mimics
WO1992004370A1 (en) 1990-08-29 1992-03-19 Vertex Pharmaceuticals Incorporated Modified di- and tripeptidyl immunosuppressive compounds
GB2247456A (en) 1990-09-03 1992-03-04 Fujisawa Pharmaceutical Co Tetrahydropyrane compounds, a process for their production and a pharmaceutical composition containing the same
JPH04149166A (en) 1990-10-12 1992-05-22 Nippon Kayaku Co Ltd Novel keto acid amide derivative
WO1992016501A1 (en) 1991-03-20 1992-10-01 Vertex Pharmaceuticals Incorporated Tetrahydroxyalkane derivatives as inhibitors of hiv aspartyl protease
IT1245712B (en) 1991-04-09 1994-10-14 Boehringer Mannheim Italia USEFUL HETEROCYCLIC AMINES THERAPY OF ASTHMA AND AIRWAY INFLAMMATION
US5147877A (en) 1991-04-18 1992-09-15 Merck & Co. Inc. Semi-synthetic immunosuppressive macrolides
HUT70259A (en) 1991-05-08 1995-09-28 Vertex Pharma Rfkbp: a novel isomerase and papamycin/fk506 binding protein
DK0584223T3 (en) 1991-05-09 2000-03-13 Vertex Pharma Hitherto unknown immunosuppressive compounds
MX9202466A (en) 1991-05-24 1994-06-30 Vertex Pharma NOVELTY IMMUNOSUPPRESSIVE COMPOUNDS.
JPH05178824A (en) 1991-08-05 1993-07-20 Takeda Chem Ind Ltd Asparagine derivative and its use
ZA927782B (en) 1991-10-11 1993-04-28 Ciba Geigy Novel herbicides.
AU2803692A (en) 1991-10-11 1993-05-03 Vertex Pharmaceuticals Incorporated Isolation of an mr 52,000 fk506 binding protein and molecular cloning of a corresponding human cdna
AU3278293A (en) 1991-12-20 1993-07-28 Syntex (U.S.A.) Inc. Cyclic amides of 3-amino-2-hydroxy-carboxylic acids as hiv-protease inhibitors
AU4388893A (en) 1992-05-20 1993-12-13 Vertex Pharmaceuticals Incorporated Method of detecting tissue-specific FK506 binding protein messenger RNAs and uses thereof
IT1254373B (en) 1992-05-29 1995-09-14 HETEROPROSTANOIDS, PROCEDURE FOR THEIR PREPARATION AND THEIR EMPLOYE THERAPEUTIC.
US5334719A (en) 1992-06-17 1994-08-02 Merck Frosst Canada, Inc. Bicyclic(azaaromatic)indoles as inhibitors of leukotriene bisynthesis
IS2334B (en) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl protease inhibitor of a new class of sulfonamides
NZ314207A (en) 1992-09-28 2000-12-22 Vertex Pharma 1-(2-Oxoacetyl)-piperidine-2-carboxylic acid derivatives as multi drug resistant cancer cell sensitizers
JPH06135961A (en) 1992-10-23 1994-05-17 Nippon Iyakuhin Kogyo Kk New diphynelpyrrolylfuran derivative
WO1994013629A1 (en) 1992-12-11 1994-06-23 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease
DE4302860A1 (en) 1993-01-22 1994-08-04 Chemie Linz Deutschland N-Cyclic and N, N'dicyclic ureas
US5385918A (en) 1993-02-09 1995-01-31 Miles Inc. Aminomethylene-peptides as immunosuppressants
US5252579A (en) 1993-02-16 1993-10-12 American Home Products Corporation Macrocyclic immunomodulators
US5319098A (en) 1993-05-18 1994-06-07 Celgene Corporation Process for the stereoselective preparation of L-alanyl-L-proline
IT1270882B (en) 1993-10-05 1997-05-13 Isagro Srl FUNGICIDE-BASED OLIGOPEPTIDES
ES2130452T3 (en) 1993-11-04 1999-07-01 Abbott Lab CYCLOBUTANE DERIVATIVES USED AS INHIBITORS OF SQUALENE-SYNTHESASE AND PROTEIN FARNESYL TRANSFERASE.
ATE184594T1 (en) 1994-03-07 1999-10-15 Vertex Pharma SULFONAMIDE DERIVATIVES AS ASPARTYL PROTEASE INHIBITORS
US5744485A (en) 1994-03-25 1998-04-28 Vertex Pharmaceuticals Incorporated Carbamates and ureas as modifiers of multi-drug resistance
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5856116A (en) 1994-06-17 1999-01-05 Vertex Pharmaceuticals, Incorporated Crystal structure and mutants of interleukin-1 beta converting enzyme
JP4470226B2 (en) 1994-08-18 2010-06-02 アリアド・ファーマシューティカルズ・インコーポレイテッド New multimerizing agent
IL115685A (en) 1994-11-16 2000-08-31 Vertex Pharma Amino acid derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
US5543423A (en) 1994-11-16 1996-08-06 Vertex Pharmaceuticals, Incorporated Amino acid derivatives with improved multi-drug resistance activity
US5621108A (en) 1994-12-05 1997-04-15 Trustees Of The University Of Pennsylvania Processes and intermediates for preparing macrocycles
US6037370A (en) 1995-06-08 2000-03-14 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5717092A (en) 1996-03-29 1998-02-10 Vertex Pharmaceuticals Inc. Compounds with improved multi-drug resistance activity
US6218424B1 (en) * 1996-09-25 2001-04-17 Gpi Nil Holdings, Inc. Heterocyclic ketone and thioester compounds and uses
US5945441A (en) * 1997-06-04 1999-08-31 Gpi Nil Holdings, Inc. Pyrrolidine carboxylate hair revitalizing agents
US6274602B1 (en) * 1998-06-03 2001-08-14 Gpi Nil Holdings, Inc. Heterocyclic thioester and ketone hair growth compositions and uses
JP2001516767A (en) * 1997-09-24 2001-10-02 アムジエン・インコーポレーテツド Prevention and treatment of hearing loss using sensory neurotrophic compounds
WO1999062488A1 (en) * 1998-06-03 1999-12-09 Gpi Nil Holdings, Inc. Heterocyclic thioester and ketone hair growth compositions and uses
AU5555699A (en) * 1998-08-14 2000-03-06 Gpi Nil Holdings, Inc. Compositions and uses for vision and memory disorders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040633A1 (en) * 1995-06-07 1996-12-19 Guilford Pharmaceuticals Inc. Small molecule inhibitors of rotamase enzyme activity
WO1998013343A1 (en) * 1996-09-25 1998-04-02 Guilford Pharmaceuticals Inc. Heterocyclic thioesters and ketones
WO1998013355A1 (en) * 1996-09-25 1998-04-02 Guilford Pharmaceuticals Inc. Heterocyclic esters and amides
WO1998037882A1 (en) * 1997-02-27 1998-09-03 Guilford Pharmaceuticals Inc. Method of using neurotrophic carbamates and ureas
WO1998037885A1 (en) * 1997-02-28 1998-09-03 Guilford Pharmaceuticals Inc. N-oxides of heterocyclic esters, amides, thioesters, and ketones

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOORG. MED. CHEM. LETT. (1994), 4(2), 315-20 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; HOLT, DENNIS A. ET AL: "Structure-activity studies of synthetic FKBP ligands as peptidyl-prolyl isomerase inhibitors", XP002153821, retrieved from STN Database accession no. 121:224 *
HAMILTON G S ET AL: "FKBP12-binding domain analogues of FK506 are potent, nonimmunosuppressive neurotrophic agents in vitro and promote recovery in a mouse model of Parkinson's disease", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 7, no. 13, 8 July 1997 (1997-07-08), pages 1785 - 1790, XP004136300, ISSN: 0960-894X *
SNYDER S H ET AL: "Neural actions of immunophilin ligands", TRENDS IN PHARMACOLOGICAL SCIENCES,GB,ELSEVIER TRENDS JOURNAL, CAMBRIDGE, vol. 19, no. 1, 1998, pages 21 - 26, XP004107587, ISSN: 0165-6147 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096420A2 (en) * 2001-05-29 2002-12-05 Guilford Pharmaceuticals Inc. Method for treating nerve injury caused by surgery
WO2002096420A3 (en) * 2001-05-29 2003-02-06 Guilford Pharm Inc Method for treating nerve injury caused by surgery
WO2003048150A1 (en) * 2001-12-06 2003-06-12 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. Substituted 5-membered n-heterocyclic compounds and their uses for treating or preventing neurodegenerative diseases
US7262183B2 (en) 2001-12-06 2007-08-28 Instititute of Pharmacology and Toxicology Substituted 5-membered n-heterocyclic compounds and their uses for treating or preventing neurodegenerative diseases
US8481711B2 (en) 2010-07-06 2013-07-09 Hidenori Kamanishi Neurite outgrowth agent

Also Published As

Publication number Publication date
MXPA02005206A (en) 2002-11-07
US20010056103A1 (en) 2001-12-27
AU784388B2 (en) 2006-03-23
CA2391575A1 (en) 2001-05-31
EP1233945A1 (en) 2002-08-28
AU7086900A (en) 2001-06-04
US20020193420A1 (en) 2002-12-19
US20040106652A1 (en) 2004-06-03
US20050148637A1 (en) 2005-07-07
JP2003514893A (en) 2003-04-22
US6417209B2 (en) 2002-07-09
US6984639B2 (en) 2006-01-10
HK1046530A1 (en) 2003-01-17
US6218424B1 (en) 2001-04-17

Similar Documents

Publication Publication Date Title
US5990131A (en) Heterocyclic thioesters and ketones
US20050148637A1 (en) Heterocyclic ketone and thioester compounds and uses
US5721256A (en) Method of using neurotrophic sulfonamide compounds
US6251892B1 (en) N-oxides of heterocyclic esters, amides, thioesters, and ketones
US5614547A (en) Small molecule inhibitors of rotamase enzyme
US6500959B1 (en) Pyrrolidine derivatives and processes for preparing same
US7056935B2 (en) Rotamase enzyme activity inhibitors
US6509477B1 (en) Small molecule inhibitors of rotamase enzyme activity
US20020042377A1 (en) Rotamase enzyme activity inhibitors
AU777188B2 (en) Heterocyclic thioesters and ketones
CA2602791A1 (en) Heterocyclic thioesters and ketones

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2391575

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000959575

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 539860

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/005206

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 70869/00

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000959575

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642